British Journal of Clinical Pharmacology

A. M. Breckenridge (Chairman)Annmarie Hedges (Press Editor)

Executive Editorial BoardJ. FeelyM. LaderM. J. S. Langman

Editorial BoardW. H. AelligL. BeeleyP. N. BennettP. BrooksD. M. Chaput de SaintongeD. Grahame-Smith

C. F. George (Editorial Secretary)

G. MawerA. N. NicholsonL. Ramsay

P. LewisJ. C. MucklowM. L'E. OrmeJ. P. PayneA. W. PeckM. Rawlins

G. T. Tucker

J. ReidA. TattersfieldP. Turner0. L. WadeF. Woods

British Journal of Clinical Pharmacology ispublished monthly by Blackwell Scientific Pub-lications Ltd for the British PharmacologicalSociety. Papers on all aspects of drug action inman will be considered for publication. Manu-scripts (four copies) and editorial correspon-dence should be addressed to Professor C. F.George, British Journal of Clinical Pharma-cology, 8 John Street, London WC1N 2ES.Papers are assumed to have been submittedexclusively to the journal as they becomecopyright on acceptance for publication. Fordetailed information, see 'Instructions toAuthors' at the front of each issue.

Subscription rates. The journal is publishedmonthly with six issues forming each volume.The subscription for 1985 is £110.00 (UK),£139.00 (overseas) and $250.00 (USA andCanada). The journal is delivered to NorthAmerica by accelerated surface post and sub-scribers there can expect to receive their copieswithin 2 weeks of British publication. Currentissues for the Indian subcontinent, Australasiaand the Far East are sent by air to regionaldistribution points from where they are for-warded to subscribers by surface mail. Anyback numbers are normally despatched by sur-face to all regions, except North America,

where they are sent by a.s.p., and India, wherethey are sent by air freight.

Copyright and photocopying. 1985 BlackwellScientific Publications Ltd. Authorization tophotocopy items for internal or personal use ofspecific clients is granted by Blackwell ScientificPublications Ltd for libraries and other usersregistered with the Copyright Clearance Center(CCC) Transactional Reporting Service, pro-vided that the base fee of $02.00 per copy ispaid directly to CCC, 27 Congress Street,Salem, Massachusetts 01970, USA. This consentdoes not extend to other kinds of copying, suchas copying for general distribution, for advertis-ing or promotional purposes, for creating newcollective works or for resale. Special requestsshould be addressed^ to Professor George.

0306-5251/85 $02.00.

Business correspondence. Orders and remit-tances relating to subscriptions and offprintsshould be sent to Blackwell Scientific Publica-tions, PO Box 88, Oxford. Advertisementbookings and enquiries should be sent to theAdvertisement Manager, Blackwell ScientificPublications, Osney Mead, Oxford OX2 OEL(telephone 0865 240201).

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statementappears in this Journal, they wish to make it dear that the data and opinions appearing in the articles and advertisements herein are theresponsibility of the contributor or advertiser concerned. Accordingly, the publishers and the editorial committee and their respectiveemployees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion orstatement.

Instructions to authors

Papers will be considered for publication on allaspects of drug action in man, including chemo-therapy. A recent issue of the Journal is a goodguide to style. Further information on style canbe found in Instructions to authors (Br. J. clin.Pharmac. 1982, 14, 3-6) and Symbols in Phar-macokinetics (Br. J. clin. Pharmac. 1982, 14,7-13).

Manuscripts (four copies) should be sent toProfessor C. F. George, British Journal ofClinical Pharmacology, 8 John Street, LondonWC1N 2ES.

1. Manuscript should be typed in double spacingon one side of standard paper (A4-206 x 294mm). There should be a separate title pagegiving the names and addresses of the authors.A short title of not more than 50 letters shouldalso be suggested. For indexing purposes asmall number (up to 5) of keywords should besupplied.

2. Statement Papers are accepted only if accom-panied by a statement that they have not beenand will not be published in whole or in part inany other Journal. Ethical considerations ofstudies reported will be particularly noted bythe Editorial Board.

3. Figures These should not be larger than A4and may be in the form of original drawings,recorded tracings or high quality photographicprints made from them. Symbols which are toappear in figures or legends should be chosenfrom the following:

O * * A A V vPhotographs and photomicrographs should beunmounted glossy bromide prints of good con-trast, well matched and preferably with a trans-parent overlay for protection. The overlay shouldbe used to indicate masking instructions, letteringor arrows.

4. Tables These should not have more than 85characters to a line (counting spaces betweencolumns as 4 characters) and certainly not morethan 110 characters to a line, unless absolutelyunavoidable. Figure legends and tables shouldbe typed on separate sheets of paper.

5. References References in the text should bequoted by the author's name(s) and year ofpublication. In the case of 2 authors both namesshould be stated. If there are more than 2authors, only the first author plus et al. should

be quoted in the text. The list of referencesshould be collected in alphabetical order at theend of the paper. The references should includethe names of all the authors, year or publication(in brackets), title of the article, title of publi-cation (abbreviated in accordance with thefourth edition of the World List of ScientificPeriodicals), volume number and first and lastpage numbers. References to books should, inaddition, include the names of the editor, theedition number, where appropriate, and thetown of origin and name of publisher. Theaccuracy of references is the responsibility ofthe author.

Two page proofs will be supplied, one of whichmay be retained by the authors. The othershould be corrected immediately and returnedto the Press Editor. Corrections should be keptto a minimum. Extensive changes may be chargedto the author.

Twenty-five offprints will be supplied to theauthors free of charge. Additional offprints canbe purchased. An offprints order form, whichshould be returned promptly, will be sent outwith the proofs. No offprints of abstracts aresupplied.

Main papers These should be divided into thefollowing sections: title page, numbered sum-mary, introduction, methods, results, dis-cussion, acknowledgements, references, tablesand figures.

Short reports These should be set out in thesame format as main papers except that theSummary should not be numbered. The length,including title, summary and references mustnot exceed 1200 words plus two figures ortables, or one of each.

Letters to the Editors Brief original communi-cations or comments upon previously publishedpapers in the Journal will be accepted underthis heading. The length, including references,must not exceed 800 words plus one figure ortable. The letter should not be divided intosections, and names and addresses of authorsshould appear at the end.

Units These are normally expressed as SI units.If other units are used a conversion factorshould be included in the Methods section. SeeEditorials, Br. J. clin. Pharmac. (1983), 16, 1,3-7.

AUTHOR INDEX

(S = supplement; L = letter to the Editors; P = proceedings)

ABADIE, F. see LECAILLON, J. B.ABERNETHY, D. R., GREENBLATT, D. J., MORSE, D. S.& SHADER, R. I. Interaction of propoxyphenewith diazepam, alprazolam and lorazepam, 51

ABERNETHY, D. R. see SCHWARTZ, J. B.ABRAMS, S. M. L. see MEKKI, Q. A.ADAMS, E. F. see STRUTHERS, A. D.ADDIS, G. J. see BRYSON, S. M.AELLIG, W. H. Pharmacological experiments in

healthy volunteers with bopindolol, a long-acting1-adrenoceptor blocking drug with partial agonistactivity, 775

AGNEW, E. see BRODIE, M. J.AGNEW, E. see MaCPHEE, G. J. A.AHOKASS, J. T. see PELKONEN, 0.AINSWORTH, S. see McBURNEY, A.ArTCHISON, T. C. see HOWIE, C. A.AJAYI, L. A. A. see HOCKINGS, N.ALBA, M. see DOMENECH, J.ALBRICI, A. see PERUCCA, E.ALDHOUS, M., FRANEY, C., WRIGHT, J. & ARENDT, J.Plasma concentrations of melatonin in man follow-ing oral absorption of different preparations, 517

ALI, N., MARSHALL, R. W. & RICHENS, A. CNS de-pressant effect of ethanol alone and in combinationwith dextropropoxyphene or meptazinol, 551P

ALLEN, E. M. see EL-BAHIE, N.ALLEN, M. see GRIFFITHS, A. N.ALLEN, W. L. see STEAD, R. J.ALLEN, W. L. see WINSTANLEY, P. A.ALLSOPP, L. F. see MULLER, F. B.AL-SAFI, S. A. & MADDOCKS, J. L. Strength of thehuman mixed lymphocyte reaction (MLR) and itssuppression by azathioprine or 6-mercaptpurine,105

AL-SAFI, S. A. see MADDOCKS, J. L.AL-SHARMA, Y. see WORTH, D. P.ALVAN, G. see SJOVALL, J.ANKIER, S. I. see MCINNES, G. T.ANTONIN, K.-H., BIECK, P., SCHEURLEN, M., JED-RYCHOWSKI, M. & MALCHOW, H. Oxprenololabsorption in man after single bolus dosing into twosegments of the colon compared with that after oraldosing, 137S

ARENDT, J. see ALDHOUS, M.ARNOLD, J. D. see GOOD, W.ARNOLD, J. M. 0. & McDEvrrr, D. G. Indirect blood

pressure measurement during intravenous isopre-naline infusions, 114L

ARNOLD, J. M. O., O'CONNOR, P. C., RIDDELL, J. G.,HARRON, D. W. G., SHANKS, R. G. & McDEvrrr,D. G. Effects of the 02-adrenoceptor antagonistICI 118,551 on exercise tachycardia and isoprenaline-induced ,B-adrenoceptor responses in man, 619

ARNOLD, J. M. 0. see O'CONNOR, P. C.

ARR, S. see SKEHAN, J. D.ARR, S. M. see VANDENBURG, M. J.ASCALONE, V. see STOECKEL, K.ASHBY, L. see POSNER, J.AVIRAM, M., VINTERSTEIN, G. & BROOK, J. G. Dif-

ferential effect of platelet inhibitors in normal and inhypercholesterolaemic subjects, 715

AWADZI, K. see EDWARDS, G.AYER, A. see THEEUWES, F.

BACK, D. J., GRIMMER, S. F. M., ORME, M. L'E.,ROGERS, S. M. & STODDARD, C. J. Intestinal trans-port and metabolism of ethinyloestradiol in vitro,146P

BACK, D. J. see GRIMMER, S. F.BACK, D. J. see STEAD, R. J.BACK, D. J. see WINSTANLEY, P. A.BAIRD, A. see NUNN, B.BAKER, L. R. I. see MATHEY, F.BAKER, S. see BUSS, D. C.BAKSHI, M. see MacMAHON, B.BALL, S. G. see CLELAND, J. G. F.BARBER, H. see HAMILTON, M. J.BARCLAY, S. P. see WARRINGTON, S. J.BARENDREGT, J. N. M. see STRICKER, B. H. CH.BARNES, J. N. see DREW, P. J. T.BARNES, N. C. see ZAKRZEWSKI, J. T.BARNES, P. J. see WARREN, J. B.BARRY, H. see O'BOYLE, C. A.BATTEN, J. C. see STEAD, R. J.BATY, J. see ISLES, T. E.BAUMELOU, H. see MERDJAN, H.BAx, N. D. S., JONES, R. W., LENNARD, M. S.,TUCKER, G. T. & WOODS, H. F. Penbutolol andpropranolol: a comparison of their effects on anti-pyrine clearance in man, 593

BAx, N. D. S., JONES, R. W., LENNARD, M. S.,TUCKER, G. T. & WOODS, H. F. The effect of pen-butolol and propranolol on antipyrine kinetics, 120P

BAx, N. D. S., TUCKER, G. T., LENNARD, M. S. &WOODS, H. F. Impairment of lignocaine clearanceby propranolol-major contribution of enzyme in-hibition, 589P

BAx, N. D. S., TUCKER, G. T., LENNARD, M. S.& WOODS, H. F. The impairment of lignocaine clear-ance by propranolol-major contribution ofenzyme inhibition, 597P

BEATE, J. M. see RAE, A. P.BEAUNE, P. see BOOBIS, A. R.BELL, G. D. see KAMALI, F.BENITEZ, J. see NORDIN, C.BENNETr, E. D. & DAVIS, A. L. A possible explanation

for the absence of anti-anginal properties of trans-dermal nitroglycerin units: an echocardiographicstudy, 435

863

864 IndexBENNETT, J. see BENNETT, P. N.BENNETT, P. N., BENNETT, J., BRADBROOK, I.,

FRANCIS, J., JOHN, V. A., ROGERS, H., TURNER, P.& WARRINGTON, S. J. Single-dose pharmacokineticand pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms ofoxprenolol in healthy volunteers, 171S

BENNETT, P. N., JOHN V. A. & KENDALL, M. J. Orosdrug delivery systems for the ,-adrenoceptor anta-gonists: oxprenolol and metoprolol, 63S

BENNETT, S. see BLAND, J. M.BERGLUND, G. see BERGSTRAND, R.BERGSTRAND, R., HERLITZ, H., JOHANNSSON, S.,BERGLUND, G., VEDIN, A., WILHELMSSON, C.,GOMEZ, H. J., CIRILLO, V. J. & BOLOGNESE, J. A.Effective dose range of enalapril in mild to moder-ate essential hypertension, 605

BERNIER, J. J. see EVARD, D.BERNIER, J. J. see GODBILLON, J.BERNIER, J. J. see JOBIN, G.BERNIER, J. J. see VIDON, N.BERTILSSON, L. see NORDIN, C.BEST, N. R., COWEN, P. J., ELLmOTT, J. M., FRASER, S.,GOSDEN, B. & STUMP, K. Changes in imipramine anda2-adrenoceptor binding sites in the early puerper-ium, 555P

BEVAN, J. S. see COWEN, P. J.BEWICK, M. see HOLT, D. W.BHATTACHARJEE, P. see WALDEN, R. J.BIANCO, L. see GHIRHARDI, P.BIECK, P. see ANTONIN, K.-H.BIRMINGHAM, A. T. see PATRICK, J. M.BIRNIE, G. G. see BRODIE, M. J.BLANCHARD, J., SAWERS, S. J. A., JONKMAN, J. H. G.& DAN-SHYA TANG-LIU, D. Comparison of theurinary metabolic profile of caffeine in young andelderly males, 225

BLAND, J. M., JONES, D. R., BENNETT, S., COOK,D. G., HAINES, A. P. & MacFARLANE, A. J. Is theclinical trial evidence about new drugs statisticallyadequate? 155

BLYDEN, G. T. see GREENBLATT, D. J.BOLLI, P. see MULLER, F. B.BOLOGNESE, J. A. see BERGSTRAND, R.BOOBIS, A. R., HAMPDEN, C. E., MURRAY, S.,BEAUNE, P. & DAVIS, D. S. Attempts to pheno-type human liver samples in vitro for debriso-quine 4-hydroxylase activity, 721

BOOBIS, A. R., TEE, L. B. G., HAMPDEN, C. E.,HUGGETT, A. C. & DAVIES, D. S. Comparativeability of man to activate paracetamol to its hepato-toxic metabolite, 590P

BOOBIS, A. R. see TEE, L. B. G.BORCHARD, U. see BRINKMANN, M.BOSCH, E. see MALAN, J.BOSSuYT, A. M. see DUPONT, A. G.BOUCHIER, A. D. see SHEPHERD, A. N.BOURNE, D. W. A. see Ho, P. C.BOVET, M. see EVARD, D.BOYCE, M., DALTON, N., GOODWIN, B., WALKER, P.,WEG, M. & SANDLER, M. Disposition of equimolardoses of epinine and ibopamine, the di-isobutyrylester of epinine, in healthy subjects, 143P

BRADBROOK, I. D., JOHN, V. A., MORRISON, P. J.,ROGERS, H. J. & SPECTOR, R. G. Pharmacokineticinvestigation of the absorption of oxprenolol from

Oros delivery systems in healthy volunteers: com-parison of in vivo and in vitro drug release, 163S

BRADBROOK, I. see BENNETT, P. N.BRADDOCK, L. E. see COWEN, P. J.BRADSHAW, C. M. see BUCETA, J. M.BRADSHAW, C. M. see LONGMORE, J.BRAITHWAITE, P. A. see DAWSON, M.BRANAGAN, P. see MacMAHON, B.BRECKENRIDGE, A. M. see EDWARDS, G.BRECKENRIDGE, A. M. see MIHALY, G. W.BRECKENRIDGE, A. M. see SCOTT, A. K.BRECKENRIDGE, A. M. see WARD, S. A.BRECKENRIDGE, A. M. see WINSTANLEY, P. A.BREIMER, D. D., JOCHEMSEN, R., KAMPHUISEN,H. A. C., NICHOLSON, A. N., SPENCER, M. B. &STONE, B. M. Central effects during the continuousosmotic infusion of a benzodiazepine (triazolam),554P

BREIMER, D. D., JOCHEMSEN, R., KAMPHUISEN,H. A. C., NICHOLSON, A. N., SPENCER, M. B. &STONE, B. M. Central effects during the continuousosmotic infusion of a benzodiazepine (triazolam),807

BREIMER, D. D. see KLEINBLOESEM, C. H.BRINKMANN, M., BORCHARD, U., BRODDE, O.-E.,DAUL, A., O'HARA, N. & SCHEMUTH, R. Alterationof human lymphocyte 032-adrenoceptor density by02-adrenoceptor blocker administration: the roleof ISA, 588P

BRINKMANN, M., BRODDE, O.-E., DAUL, A., O'HARA,N. & SCHEMUTH, R. Reversal of agonist-inducedhuman lymphocyte 02-adrenoceptor desensitiza-tion by prednisone and ketotifen, 587P

BROCKMEYER, N., DYELWICZ, P., HABICHT, H. &OHNHAUS, E. E. The metabolism of diazepamfollowing different enzyme inducing agents, 544P

BRODDE, O.-E. see BRINKMANN, M.BRODIE, M. J., FITzsIMMONS, C., CZARNECKI, D.,COOK, A., SCOBIE, G. & BIRNIE, G. G. Hepaticmetabolic function in psoriatics receiving long termmethotrexate therapy, 569P

BRODIE, M. J., MUIR, S. E., AGNEW, E., MacPHEE,G. J. A., VOLO, G., TEASDALE, E. & MacPHERSON,P. Protein binding and CSF penetration ofphenytoin following acute oral dosing in man, 161

BRODIE, M. J. see MaCPHEE, G. J. A.BRODIE, M. J. see MCINNES, G. T.BROOK, J. G. see AVIRAM, M.BROOKS, B. A. see McNABB, W. R.BROUGHTON PIPKIN, F. see O'BRIEN, P. M. S.BROWN, A. N. see O'CONNOR, P. C.BROWN, J. see HARVEY, J. N.BROWN, M. J. & STRUTHERS, A. D. Guanfacine lowersplasma noradrenaline by peripheral cL2-adreno-ceptor stimulation in man, 534P

BROWN, M. J. see STRUTHERS, A. D.BRUSONI, B. see GHIRHARDI, P.BRYSON, S. M., MCGOVERN, E. M., KELMAN, A. W.,WHITE, K., ADDIS, G. J. & WHITING, B. The phar-macokinetics of high dose metoclopramide inpatients with neoplastic disease, 757

BUCETA, J. M., BRADSHAW, C. M. & SZABADI, E.Hyper-responsiveness of eccrine sweat glands tocarbachol in anxiety neurosis: comparison of maleand female patients, 817

BUCHANAN, N. see MaCKINTOSH, D.

BUHLER, F. R. see MULLER, F. B.BUNTING, E. A. see MCINNES, G. T.BURGOYNE, W. see COOK, P. J.BURKE, C. see HAMILTON, M. J.BUSH, R. see COOK, P. J.BUSS, D. C., EBDEN, P., BAKER, S. & ROUTLEDGE,

P. A. Protein binding of theophylline, 529LBUss, D. C. see LEOPOLD, D.BUss, D. C. see WATT, A. H.BYE, A. see WHITEMAN, P. D.

CALDWELL, J. & COTGREAVE, I. A. The metabolic fateof ethylenediamine in man in relation to acetylatorstatus, 148P

CANNON, J. see SCOTT, A. K.CARTER, A. J. see COWLEY, A. J.CHAMBERLAIN, P. D. see NUNN, B.CHAMPION, D. see LEE, E. J. D.CHAN, E., O'REILLY, R. & ROWLAND, M. Stereoche-

mical aspects of warfarin in man: a combined phar-macokinetic-pharmacodynamic model, 545P

CHAN, E., PEGG, M., MacKAY, A. D., COLE, R. B. &ROWLAND, M. Stereochemical aspects ofwarfarin inpatients receiving chronic therapy, 571P

CHAN, K., TEOH, R. & SAMARASINGHE, H. T. Plasmaconcentrations of antiepileptic drugs in mentallyhandicapped children with epilepsy, 125P

CHANNER, K. S. & ROBERTS, C. J. C. The kinetics andCNS effects of zopiclone depend upon posture attime of administration, 152P

CHANTHAVANICH, P. see WARD, S. A.CHAPRON, D. J., SWEENEY, K. R., FEIG, P. U. &KRAMER, P. A. Influence of advanced age on thedisposition of acetazolamide, 363

CHAPUT DE SAINTONGE, D. M. see PASIC, J.CHESTNUTT, W. N., CLARKE, R. S. J. & DUNDEE, J. W.

Side effects of nalbuphine, 580PCHIANG, B. N. see HONG, C. Y.CHICK, 0. see MERDJAN, H.CHILTON, A. see THOMAS, M.CHURCH, M. K. see KIM, Y.-Y.CIRILLO, V. J. see BERGSTRAND, R.CLAAS, F. H. J. see STRICKER, B. H. CH.CLARE, A. Introduction, 5SCLARKE, R. S. J. see CHESTNUTT, W. N.CLARKE, R. S. J. see GIBSON, F. M.CLAYTON, J. K., LEES, J. & SENIOR, J. The responses

of human myometrial strips to leukotrienes, 573PCLELAND, J. G. F., DARGIE, H. J., GILLEN, G., HODS-MAN, G. P., BALL, S. G. & ROBERTSON, J. I. S.Effects of enalapril on clinical state and serum elec-trolytes in congestive heart failure, 542P

COELHO, J., SCHNELLE, K., JOUBERT, L., VENTURA,D. & MULLANE, J. Dynamics of 1-adrenoceptorblockade with cetamolol, 411

COHEN, A. F. see POSNER, J.COL, J. see GHIRHARDI, P.COLE, R. B. see CHAN, E.COLLIER, P. S. see FEE, J. P; H.COLLIER, P. S. see HALLIDAY, N. J.COLLINS, P. J. see HOROWrTZ, M.COOK, A. see BRODIE, M. J.COOK, D. G. see BLAND, J. M.COOK, P. J., BURGOYNE, W., LOGAN, L., BUSH, R. &DAWLING, S. Temazepam half-life in fasting and

Index 865nonfasting subjects, the relation to FFA and diaze-pam protein binding, 587P

COOKE, J. see PRICE, D.COOPER, G. L. see MULLER, F. B.COOPER, S. J., KING, D. J. & LEAHEY, W. J. ECT,dopamine and delusions, 551P

COOPER, W. D. see VANDENBURG, M. J.CORTOT, A. see JOBIN, G.COSTELLO, J. F. see ZAKRZEWSKI, J. T.COTGREAVE, I. A. see CALDWELL, J.COUNIHAN, H. E. see CROWE, M. J.COWEN, P. J., BEVAN, J. S., GOSDEN, B. & ELLIOTT,

S. A. Treatment with 1-adrenoceptor blockers re-duced plasma melatonin concentration, 258

COWEN, P. J., BRADDOCK, L. E., GREEN, A. R. &GRAHAME-SMITH, D. G. Noradrenergic transmissionin the pineal gland during desmethylimipraminetreatment, 579P

COWEN, P. J., GREEN, A. R. & GRAHAME-SMITH, D. G.& BRADDOCK, L. E. Plasma melatonin duringdesmethylimipramine treatment: evidence forchanges in noradrenergic transmission, 799

COWEN, P. J. see BEST, N. R.COWEN, P. J. see SCHACHTER, M.COWIE, A. see GRIMMER, S. F.COWLEY, A. J., JONES, E. W., CARTER, A. J., HANLEY,

S. P. & HEPTrINSTALL, S. The effects ofdazoxiben, aninhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and plateletbehaviour in different individuals, 1

CREASY, W. A., PLATT, T. B., FRANTZ, M. &SUGERMAN, A. A. Pharmacokinetics of aztreonamin elderly male volunteers, 233

CREEK, R. A. & LADER, M. H. Preface, 3SCREGEEN, R. see HARVEY, J. N.CROME, P., GAIN, R., SURI, A. C. & DAWLING, S.Temazepam in elderly women: single and multipledose kinetics and effects on psychomotor perform-ance, 583P

CRONIN, C. J. see TOMLINSON, B.CROWE, M. J., COUNIHAN, H. E. & O'MALLEY, K. A

comparative study of a new selective 12-adreno-ceptor agonist, procaterol, and salbutamol inasthma, 787

CUBELA, R. see LARMOUR, I.CULLEN, J. see O'BOYLE, C. A.CURRIE, W. J. C. see VANDENBURG, M. J.CURRY, S. H. & KWON, H.-R. Influence of posture onplasma nitroglycerin, 403L

CUSS, F. see WARREN, J. B.CZARNECKI, D. see BRODIE, M. J.

DALTON, N. see BOYCE, M.DANESHMEND, T. K. see HOMEIDA, M. A.DANQUECHIN-DORVAL, E. see JOBIN, G.DAN-SHYA TANG-LIU, D. see BLANCHARD, J.DARGIE, H. J. see CLELAND, J. G. F.DARGIE, H. J. see FINDLAY, I. N.DAUL, A. see BRINKMANN, M.DAVIES, A. L. see BENNETT, E. D.DAVIS, D., GROSSMAN, KITCHELL, B. B., SHAND, D. G.& ROUTLEDGE, P. A. The effects of age and smokingon the plasma protein binding of lignocaine anddiazepam, 261

DAVIES, D. S. see BOOBIS, A. R.

866 IndexDAVIES, D. S. see SHAFFER, J. L.DAVIES, D. S. see TEE, L. B. G.DAVIES, I. B. see KILFEATHER, S. A.DAVISON, K., FARQUHARSON, R. G., KHAN, M. C. &MAJID, A. A double-blind comparison of alprazo-lam, diazepam and placebo in the treatment ofanxious out-patients, 37S

DAWLING, S. see COOK, P. J.DAWLING, S. see CROME, P.DAWSON, M. & WATSON, T. R. The effect of dose formon the bioavailability of mebendazole in man, 87

DAWSON, M., BRAITHWAITE, P. A., ROBERTS, M. S. &WATSON, T. R. The pharmacokinetics andbioavailability of a tracer dose of [3H]-mebendazolein man, 79

DAY, R. see LEE, E. J. D.DAYA, S. see VENTER, C. P.DEBBAS, N. M. G., JACKSON, S. H. D., & TURNER, P. A

study of the haemodynamic effects of nicardipineinfusion in man, 563P

DEGANI, N. C. see SELLERS, E. M.DEGEN, P. H. see MOPPERT, J.DEI CAS, L. see GHIRHARDI, P.DENNIS, M. J. see HOUGHTON, G. W.DENTON, A. see RAMAGE, J. K.DEVLIN, R. G. see FLEISS, P. M.DIQUET, B. see MERDJAN, H.DOENICKE, A. see KLOTZ, U.DOLLERY, C. T. see STRUTHERS, A. D.DOMENECH, J., ALBA, M., MORERA, J. M., OBACH, R.& PLA DELFINA, M. Gastric, intestinal and colonicabsorption of metoprolol in the rat, 85S

DOROW, R. see KLOTZ, U.D0SSING, M. see LOFr, S.Dow, R. J. see ISLES, T. E.Dow, R. see JAMIESON, M. J.DOWNEY, K. M. see PASIC, J.DREW, P. J. T., BARNES, J. N. & EVANS, S. J. W. The

effect of acute P-adrenoceptor blockade on exami-nation performance, 783

DUBACH, U. C. see STOECKEL, K.DUKA, T H. see KLOTZ, U.DUNAGAN, F. M., KELMAN, A. W., MCGILL, P. E. &WHITING, B. Estimation of the NSAID concentra-tion-effect relationship in rheumatoid arthritis,548P

DUNDEE, J. W., WILSON, C. M., ROBINSON, F. P.,THOMPSON, E. M. & ELLIOTT, P. The effect of raniti-dine on the hypnotic action of single doses of mida-zolam, temazepam and zopiclone, 553P

DUNDEE, J. W. see CHESTNUTT, W. N.DUNDEE, J. W. see FEE, J. P. H.DUNDEE, J. W. see HALLIDAY, N. J.DUNN, M. J. see RITTER, J. M.DUPONT, A. G., BOSSUYr, A. M., JONCKHEER, M. H.& Six, R. 0. Effect of nadolol on ambulatory bloodpressure, renal haemodynamics and cardiac func-tion in hypertension, 129P

DUSING, R., MORITZ, K., GLANZER, K. & FRAMER,H. J. Effect of angiotensin II and captopril on renaltubular function in man, 29

DUVAL, M. see EVARD, D.DUVAL, M. see GODBILLON, J.DUVAL, M. see JOBIN, G.DUVAL, M. see VIDON, N.

DWORZAK, F. see EDWARDS, R. H. T.DYELWICZ, P. see BROCKMEYER, N.

EARLEY, B. see O'CONNOR, W. T.EBDEN, P. see Buss, D. C.EDWARDS, C. see RYLANCE, G. W.EDWARDS, G., AWADZI, K., JOHNSON, C. L., BRECK-ENRIDGE, A. M. & ORME, M. L'E. The influence ofurine alkalinisation on the pharmacokinetics andclinical effects of diethylcarbamazine, 545P

EDWARDS, G. see MIHALY, G. W.EDWARDS, G. see WARD, S. A.EDWARDS, R. H. T., DWORZAK, F., GERBER, P. P.,GRIGGS, R. C., FORD, C., HALLIDAY, D. & RENNIE,M. J. Stanozolol in patients with muscular dystro-phy increases muscle protein synthesis measured invivo with stable isotopes, 124P

EHSANULLAH, M., LEE, D. A. H., WILLIAMS, T., POL-LARD, P. & GAZZARD, B. The effect of secoverinehydrochloride on stimulated sigmoid motility: adouble-blind, placebo controlled cross-over study inirritable bowel syndrome, 301

EL-BAHIE, N., ALLEN, E. M., WILLIAMS, J. & ROUT-LEDGE, P. A. The effect of activated charcoal andhyoscine butylbromide alone and in combination onthe absorption of mefanamic acid, 836

EL DEBANI, A. H. see MaCWALTER, R. S.ELLIOTT, A. T. see FINDLAY, I. N.ELLIOTT, H. L. see MEREDITH, P. A.ELLIOTT, H. L. see PASANISI, F.ELLIOTT, J. M. see BEST, N. R.ELLIOTT, J. M. see SCHACHTER, M.ELLIOTT, J. M. see NUTT, D. J.ELLIOTT, P. see DUNDEE, J. W.ELLIOTT, S. A. see COWEN, P. J.ENDELE, R. see STAIGER, CSC.ENE, M. D., WILLIAMSON, P. J., ROBERTS, C. J. C. &WADDELL, G. The natriuresis following oraladministration of the calcium antagonists-nifedipine and nitrendipine, 423

EVALDSON, G. R., LINDGREN, S., NORD, C.-E. &RANE, A. T. Tinidazole milk excretion and pharma-cokinetics in lactating women, 503

EVANS, N. J., RUTTER, N., PARR, G. & HADGRAFT, J.Percutaneous theophylline administration to thepreterm neonate, 125P

EVANS, S. J. W. Correction equation for ECG timeintervals, 860L

EVANS, S. J. W. see DREW, P. J. T.EVANS, S. J. W. see WALDMANN, C. S.EVARD, D., VIDON, N., GODBILLON, J., BOVET, M.,DUVAL, M., SCHOELLER, J. P., BERNIER, J. J. &HIRTZ, J. Investigation of drug absorption from thegastrointestinal tract of man. IV. Influence of foodand digestive secretions on metoprolol jejunalabsorption, 119S

EVARD, D. see GODBILLON, J.EVARD, D. see VIDON, N.EWEN, S. W. see NYEMITEI-ADDO, I.

FAIRRIS, G. M. & FAIRRIS, N. Cimetidines's effect ondermal H,-receptor antagonist tolerance, 272

FAIRRIS, N. see FAIRRIS, G. M.FARA, J. W., MYRBACK, R. E. & SWANSON, D. R.

Evaluation of oxprenolol and metoprolol Oros sys-

tems in the dog: comparison of in vivo and in vitrodrug release, and of drug absorption from duodenaland colonic infusion sites, 91S

FARQUHARSON, R. G. see DAVISON, K.FARROW, P. R. see McBURNEY, A.FEE, J. P. H., MCCLEAN, E., COLLIER, P. S. & DUNDEE,

J. W. Plasma diazepam concentrations followingintravenous Valium and Valium mixed micelles,581P

FEELY, J. see MacWALTER, R. S.FEELEY, M. see PRICE, D.FEIG, P. U. see CHAPRON, D. J.FERGUSON, I. see GUAY, D. R. P.FERRERO, E. see PERUCCA, E.FEYERABEND, C., INGS, R. M. & RUSSELL, M. A. H.

Nicotine pharmacokinetics and its application tointake from smoking, 239

FIFIELD, R. A. see LEOPOLD, D.FILE, S. E. & LISTER, R. G. A comparison of the effects

of lorazepam with those of propranolol onexperimentally-induced anxiety and performance,445

FINCH, M. B. & JOHNSTON, G. D. The acute peripheralvascular effects of diltiazem in man-dose-responsecharacteristics, 131P

FINCH, M. B. see JOHNSTON, G. D.FINCH, M. B. see O'CONNOR, P. C.FINDLAY, I. N., DARGIE, H. J. & KRIKLER, D. M. The

treatment of angina pectoris in patients with chronicobstructive airways disease, 150P

FINDLAY, I. N., DARGIE, H. J., GILLEN, G. & ELLIOTT,A. T. Effects on cardiac function, heart rate andblood pressure during combination therapy withverapamil and atenolol, 565P

FITZHARRIS, P., MCLEAN, A. E. M., SPARKS, R. G.,WEATHERLEY, B. C., WHITE, R. D. & WOOTTON, R.The effects in volunteers of BW12C, a compounddesigned to left-shift the blood oxygen saturationcurve, 471

FITZSIMMONS, C. see BRODIE, M. J.FLASKOS, J., GEORGE, A. J. & THEOPHILOPOULOS, N.

Platelet 5-HT uptake in obsessional neurosis andneurotic depression, 556P

FLEISS, P. M., RICHWALD, G. A., GORDON, J., STERN,M., FRANTZ, M. & DEVLIN, R. G. Aztreonam inhuman serum and breast milk, 509

FOLLATH, F. see VOZEH, S.FOLTZ, R. L. see SELLERS, E. M.FONG, J. C. see HONG, C. Y.FORD, C. see EDWARDS, R. H. T.FORGO, I. see STOECKEL, K.FORSTER, J. K. see MACONOCHIE, J. G.FOWLE, S. E. see WHITEMAN, P. D.FOWLER, P. A. see MACONOCHIE, J. G.FOWLER, P. see THOMAS, M.FRANCIS, J. see BENNETT, P. N.FRANCIS, R. J. see O'CONNOR, P. C.FRANEY, C. see ALDHOUS, M.FRANTZ, M. see CREAST, W. A.FRANTZ, M. see FLEISS, P. M.FRASER, S. see BEST, N. R.FRASER, S. see NUTT, D. J.FREI, P. see MULLER, F. B.FRY, J. R. & KAMALI, F. Effects of probenecid on

paracetamol metabolism and excretion in man,590P

Index 867FRY, J. R. see KAMALI, F.FURLANUT, M., MONTANARI, G. & RUSCA, F. Possible

interaction between aminophylline and ascorbicacid, 528L

GABRIEL, R. see HOUGHTON, G. W.GAIN, R. see CROME, P.GALLOWAY, D. B. see O'CONNOR, P. C.GARD, P. R. see RYLANCE, G. W.GAZZARD, B. see EHSANULLAH, M.GEANEY, D. P. see SCHACHTER, M.GEORGE, A. J. see FLASKOS, J.GERARDIN, A. see GODBILLON, J.GERBER, P. P. see EDWARDS, R. H. T.GHIRHARDI, P., BRUSONI, B., MANGIAVACCHI, M.,BIANCO, L., COL, J., METRA, M. & DEI CAS, L.Acute haemodynamic effects of ibopamine inpatients with severe congestive heart failure, 613

GIBSON, F. M., MIRAKHUR, R. K. & CLARKE, R. S. J.Potency of vecuronium: comparison of single bolusdose and cumulative dose techniques, 552P

GILLEN, G. see CLELAND, J. G. F.GILLEN, G. see FINDLAY, I. N.GILMORE, I. see GRIMMER, S. F.GLANZER, K. see DOSING, R.GLAUS, L. see MULLER, F. B.GLOVER, V. see LITrLEWOOD, J. T.GODBILLON, J., EVARD, D., VIDON, N., DUVAL, M.,SCHOELLER, J. P., BERNIER, J. J. & HIRTZ, J. Investi-gation of drug absorption from the gastrointestinaltract of man. III. Metoprolol in the colon, 113S

GODBILLON, J., GERARDIN, A., RICHARD, J., LEROY,D. & MOPPERT, J. Osmotically controlled-delivery ofmetoprolol in man: in vivo performance of Orossystems with different durations of drug release,213S

GODBILLON, J. see EVARD, D.GODBILLON, J. see JOBIN, G.GODBILLON, J. see VIDON, N.GOLDHILL, D. R. see WALDMANN, C. S.GOLDIE, C. see MaCPHEE, G. J. A.GOMEZ, H. J. see BERGSTRAND, R.GOOD, W., LEESON, L. J., ZAK, S. L., WAGNER, W. E.,MEEKER, J. B. & ARNOLD, J. D. Oros controlled-release formulations of metoprolol: an approach tothe development of a system for once daily adminis-tration, 231S

GOOD, W. see WARRINGTON, S. J.GOODWIN, B. see BOYCE, M.GORDON, J. see FLEISS, P. M.GORGOLEWSKA, G. see KILFEATHER, S. A.GOSDEN, B. see BEST, N. R.GOSDEN, B. see COWEN, P. J.GOSDEN, B. see NuTr, D. J.GRAHAM, B. R. see TOMLINSON, B.GRAHAM, B. R. see WALDEN, R. J.GRAHAM, D. see JAMIESON, M. J.GRAHAM, G. see LEE, E. J. D.GRAHAME-SMITH, D. G. see COWEN, P. J.GRAHAME-SMITH, D. G. see SCHACHTER, M.GRAINGER, S. L., JOHN, V. A., SHOTTON, P. A. &

SMITH, S. E. A multiple dose pharmacokineticand pharmacodynamic evaluation of conven-

tional and 19/285 Oros formulations ofmetoprolol in healthy volunteers, 239S

GREEN, A. R. see COWEN, P. J.

868 IndexGREENBLATF, D. J., MATLIS, R., SCAVONE, J. M.,BLYDEN, G. T., HARMATZ, J. S. & SHADER, R. I.Oxaprozin pharmacokinetics in the elderly, 373

GREENBLATT, D. J. see ABERNETHY, D. R.GREENWOOD, R. N. see MATTHEY, F.GRIWTHS, A. N., JONES, D. M., MARSHALL, R. W.,ALLEN, E. M. & RICHENS, A. A comparison of thepsychomotor effects of zopiclone with three mar-keted benzodiazepines and placebo, 584P

GRIGGS, R. C. see EDWARDS, R. H. T.GRIMMER, S. F., BACK, D. J., ORME, M. L'E., COWIE,

A., GILMORE, I. & TjIA, J. The bioavailability ofethinyloestradiol and levonorgestrel in patients withan ileostomy, 572P

GRIMMER, S. F. M. see BACK, D. J.GRIMMER, S. F. M. see STEAD, R. J.GROSSMAN, S. H. see DAVIS, D.GUAY, D. R. P., MEATHERALL, R. C., FERGUSON, I.,

SMITH, H. & LIGHT, B. Mexiletine clearance duringperitoneal dialysis, 857

GUITTARD, G. see THEEUWES, F.

HABICHT, H. see BROCKMEYER, N.HADGRAFT, J. see EVANS, N. J.HAFIZULLAH, M. see JACKSON, N. C.HAINES, A. P. see BLAND, J. M.HAINSWORTH, R. see WORTH, D. P.HALLIDAY, D. see EDWARDS, R. H. T.HALLIDAY, N. J., DUNDEE, J. W., COLLIER, P. S. &HOWARD, P. J. Effects of aspirin pretreatment onthe in vitro serum binding of midazolam, 581P

HALSEY, A. see WOODS, K. L.HAMILTON, C. A. see SELLERS, E. M.HAMILTON, M. J., BARBER, H., BURKE, C., LETLEY, E.OWEN, R. & PECK, A. W. Antihistamine drowsiness:effects of triprolidine and BW825C on repeatedadministration, 585P

HAMPDEN, C. E. see BOOBIS, A. R.HANLEY, S. P. see COWLEY, A. J.HARMATZ, J. S. see GREENBLATT, D. J.HARRIS, D. see O'BOYLE, C. A.HARRON, D. W. G., NICHOLLS, D. P. & SHANKS, R. G.

Indoramin-prolongation of repolarization time, amechanism of bradycardia in man? 266

HARRON, D. W. G. see ARNOLD, J. M. 0.HARRON, D. W. G. see NICHOLLS, D. P.HARRON, D. W. G. see O'CONNOR, P. C.HARRON, D. W. G. see RIDDELL, J. G.HARRY, J. see ROBB, 0. J.HARVEY, J. N., WORTH, D. P., BROWN, J. & LEE, M. RThe effect of oral fenoldopam (SKF 82526-J), aperipheral dopamine receptor agonist, on bloodpressure and renal function in normal man, 21

HARVEY, J. N., WORTH, D. P., CREGREEN, R. & LEE,M. R. Fenoldopam (SKF 82526), a dopaminergicvasodilator: studies in essential hypertension, 143P

HARVEY, J. N. see WORTH, D. P.HASSAN, S. M., WAINSCOTr, G. & TURNER, P. A com-

parison of the effect of paroxetine and amitriptylineon the tyramine pressor response test, 705

HAWKSWORTH, G. M. see NYEMITEI-ADDO, I.HAXHOLDT, 0. see LoFr, S.HAYES, P. C. see SHEPHERD, A. N.HEAPY, C. G. see O'NEILL, P. A.HEAZLEWOOD, V. J. see Ho, P. C.

HEINTZ, R. C. see STOECKEL, K.HEMPENIUS, J. see JONKMAN, J. H. G.HENDERSON, A. & JOLLIFFE, D. Cardiac effects ofsodium stibogluconate, 73

HENNES, U. see STOECKEL, K.HEPTINSTALL, S. see COWLEY, A. J.HERLITZ, H. see BERGSTAND, R.HILL, T. W. K. see MacLEOD, D.HIRTZ, J. The gastrointestinal absorption of drugs inman: a review of current concepts and methods ofinvestigation, 77S

HIRTZ, J. see EVARD, D.HIRTZ, J. see GODBILLON, J.HIRTZ, J. see JOBIN, G.HIRTZ, J. see VIDON, N.Ho, P. C., TRIGGS, E. J., BOURNE, D. W. A. &HEAZLEWOOD, V. J. The effects of age and sex onthe disposition of acetylsalicylic acid and its meta-bolites, 675

HOBSON, D. see WINSTANLEY, P. A.HOCKINGS, N., AJAYI, L. A. A., HUGHES, D. M., LEES,

K. R. & REID, J. L. Effects of age on the pharma-codynamic responses to the angiotensin convertingenzyme inhibitors enalapril and enalaprilat, 140P

HODSMAN, G. P. see CLELAND, J. G. F.HODSON, M. E. see STEAD, R. J.HOLGATE, A. M. & READ, N. W. Metoclopramide

reduces carbohydrate absorption in man, 67HOLGATE, S. T. see KIM, Y.-Y.HOLGATE, S. T. see MANN, J. S.HOLT, D. W., MARSDEN, J. T., ROGERSON, M. E.,

REID, K. E. & BEWICK, M. The value of cyclosporinmeasurements following renal transplantation,548P

HOLTKAMP, A. see JONKMAN, J. H. G.HOMEIDA, M. A. & DANESHMEND, T. K. Antipyrinemetabolism in hepatocellular carcinoma, 570P

HONG, C. Y., CHIANG, B. N., Ku, J., WEI, Y. H. &FONG, J. C. Calcium antagonists stimulate spermmotility in ejaculated human serum, 45

HONG, C. Y., CHIANG, B. N., Wu, P., WEI, Y. H. &FONG, J. C. Involvement of calcium in the caffeinestimulation of human sperm motility, 739

HORNBY, E. J. see THOMAS, M.HOROWITZ, M., COLLINS, P. J., TUCKWELL, V.,VERNON-ROBERTS, J. & SHEARMAN, D. J. C. Fen-fluramine delays gastric emptying of solid food, 849

HOROWITZ, M. see MADDERN, G. J.HOUGHTON, G. W., DENNIS, M. J. & GABRIEL, R.

Pharmacokinetics of metronidazole in patients withvarying degrees of renal failure, 203

HOUSTON, J. B. see SHAFFER, J. L.HOWARD, P. J. see HALLIDAY, N. J.HOWIE, C. A., AITCHISON, T. C., KELMAN, A. W. &WHMNG, B. A stimulation study to test a Bayesianmethod for parameter optimisation in clinical phar-macokinetics, 546P

HUGGETT, A. C. see BOOBIS, A. R.HUGHES, D. M. see HOCKINGS, N.HUGHES, J. M., SEALE, J. P. & TEMPLE, D. M. Raniti-

dine does not potentiate mediator release fromhuman lung in vitro, 711L

HUTrON, I. see RAE, A. P.

INABA, T. see JURIMA, M.

INGS, R. M. J. see MCINNES, G. T.ISLES, T. E., BATY, J. & Dow, R. J. The effect of

nicardipine, a calcium antagonist, on pituitary hor-mone release in normal volunteers, 139P

JACK, D. B., KENDALL, M. J., LAUGHER, S. J. & SMITH,S. R. Reproducibility of oxprenolol plasma concen-

trations in young female volunteers following oraladministration of an oxprenolol Oros dosage form,185S

JACK, D. B. see WOODS, K. L.JACKSON, B. see LARMOUR, I.

JACKSON, N. C., SILKE, B., LEE, P. HAFIZULLAH, M.,VERMA, S. P., REYNOLDS, G. & TAYLOR, S. H. Dose-response studies with a transdermal formulation ofnitroglycerine in angina pectoris, 561P

JACKSON, N. see SILKE, B.JACKSON, P. R., LEWIS, R. V. & RAMSAY, L. E. Rela-

tion between P-adrenoceptor blockers and de-pression assessed by visual analogue scales, 557P

JACKSON, P. R. see LEWIS, R. V.

JACKSON, S. H. D. see DEBBAS, N. M. G.JACKSON, S. H. D. see PASIC, J.

JACYNA, M. see SHEPHERD, A. N.JAMIESON, G. G. see MADDERN, G. J.JAMIESON, M. J., JEFFERS, T. A., Dow, R. & GRAHAM,D. Nicardipine infusion: pharmacokinetics, haemo-

dynamics and effects on systolic time intervals, 536LJEAL, S. see WHITEMAN, P. D.

JEDRYCHOWSKI, M. see ANTONIN, K.-H.

JEFFERS, T. A. see JAMIESON, M. J.JOBIN, G., CORTOT, A., DANQUECHIN-DORVAL, E.,GODBILLON, J., SCHOELLER, J. P., BERNIER, J. J. &

HIRTZ, J. Investigation of drug absorption from the

gastrointestinal tract in man. V. Effect of the P-adrenoceptor antagonist, metoprolol, on postpran-dial gastric function, 127S

JOBIN, G., CORTOT, A., GODBILLON, J., DUVAL, M.,SCHOELLER, J. P., HIRTZ, J. & BERNIER, J. J. Investi-

gation of drug absorption from the gastrointestinaltract of man. I. Metoprolol in the stomach, duode-

num and jejunum, 97S

JOHANSSON, S. see BERGSTRAND, R.

JOCHEMSEN, R. see BRIEIMER, D. D.

JOHN, V. A., SHOTrON, P. A., MOPPERT, J. &

THEOBALD, W. Gastrointestinal transit of Oros drugdelivery systems in healthy volunteers: a short re-

port, 203SJOHN, V. A. & SMITH, S. E. Influence of food intake on

plasma oxprenolol concentrations following oral

administration of conventional and Oros prepara-tions, 191S

JOHN, V. A. see BENNErY, P. N.JOHN, V. A. see BRADBROOK, I. D.JOHN, V. A. see GRAINGER, S. L.JOHN, V. A. see KENDALL, M. J.JOHN, V. A. see WARRINGTON, S. J.JOHN, V. A. see WOODS, K. L.JOHNSON, C. L. see EDWARDS, G.JOHNSON, D. A. W. The use of benzodiazepines in

depression, 31SJOHNSTON, A. see PASIC, J.JOHNSTON, C. I. see LARMOUR, I.JOHNSTON, G. D., O'CONNOR, P. C., NICHOLLS, D. P.,LEAHEY, W. J. & FINCH, M. B. The effects of propra-

Index 869nolol and digoxin on the acute vascular responses tofrusemide in normal man, 417

JOHNSTON, G. D., FINCH, M. B. & SHANKS, R. G.Peripheral vascular effects of bufuralol in normalsubjects and hypertensive patients: a comparisonwith propranolol and pindolol, 537P

JOHNSTON, G. D. see FINCH, M. B.JOHNSTON, G. D. see KONDOWE, G. B.JOLLIFFE, D. see HENDERSON, A.JONCKHEER, M. H. see DUPONT, A. G.JONES, C. R., WHFUE, K. F. & REID, J. L. Haemodyna-

mic, metabolic and lymphocytic 02-adrenoceptorchanges following chronic 1-adrenoceptor anta-gonism, 534P

JONES, D. M. see GRIFFITHS, A. N.JONES, D. R. see BLAND, J. M.JONES, E. W. see COWLEY, A. J.JONES, R. W. see BAX, N. D. S.JONKMAN, J. H. G., VAN DER BOON, W. J. V.,SCHOENMAKER, R., HOLTKAMP, A. & HEMPENIUS, J.Lack of effect of amoxicillin on theophylline phar-macokinetics, 99

JONKMAN, J. H. G. see BLANCHARD, J.JOUBERT, J. R. see SHEPHERD, E. G.JOUBERT, L. see COELHO, J.JOUBERT, P. H. see COELHO, J.JOUBERT, P. H. see VENTER, C. P.JUHL, R. P. see KROBOTH, P. D.JURIMA, M., INABA, T., KADAR, D. & KALOW, W.

Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals andCaucasians, 483

KADAR, D. see JURIMA, M.KAGER, L. see SAWE, J.KALOW, W. see JURIMA, M.KAMALI, F., FRY, J. R., SMART, H. L. & BELL, G. D.A double-blind placebo controlled study to examineeffects of sucralfate on paracetamol absorption,113L

KAMALI, F. see FRY, J. R.KAMPHUISEN, H. A. C. see BREIMER, D. D.KAPLAN, H. L. see SELLERS, E. M.KAUFMANN, B. see STAIGER, CSC.KAYE, C. M., MITCHELL, P. & STANLEY, C. A simpleand sensitive reverse-phase h.p.l.c. method for thespecific assay of pipothiazine in plasma, 576P

KELLY, J. G., SALEM, S. A. M., KINNEY, C. D.,SHANKS, R. G. & McDEVITr, D. G. Effects of raniti-dine on the disposition of metoprolol, 219

KELLY, J. G. see KONDOWE, G. B.KELLY, J. G. see MacMAHON, B.KELMAN, A. W., WHMNG, B. & SUMMER, D. J. Cor-

rection for ECG time intervals: a reply, 861LKELMAN, A. W. see BRYSON, S. M.KELMAN, A. W. see DUNAGAN, F. M.KELMAN, A. W. see HOWIE, C. A.KELMAN, A. W. see MEREDITH, P. A.KENDALL, M. J. & JOHN, V. A. The role of clinicalpharmacology in the development and evaluation oforal controlled-release dosage forms, 65S

KENDALL, M. J. see BENNETT, P. N.KENDALL, M. J. see JACK, D. B.KENDALL, M. J. see WILKINS, M. R.KENDALL, M. J. see WOODS, K. L.

870 IndexKERR, F. A. & SZABADI, E. Comparison of the effects

of chronic administration of ciclazindol and desipra-mine on pupillary responses to tyramine, methox-amine and pilocarpine in healthy volunteers, 639

KHAN, M. C. see DAVISON, K.KHANNA, S. see THEEUWES, F.KILFEATHER, S. A., GORGOLEWSKA, G., DAVIES, I. B.& TURNER, P. Elevated lymphocyte 3-adrenoceptordensity in multiple system atrophy with associatedsympathetic degeneration, 128P

KIM, Y.-Y., HOLGATE, S. T. & CHURCH, M. K. Inhibi-tion of histamine release from dispersed human lungand tonsillar mast cells by nicardipine and nifedi-pine, 631

KING, D. J. see COOPER, S. J.KINNEY, C. D. see KELLY, J. G.KIRBY, J. D. T. see SOWEMIMO-COKER, S. 0.KITCHELL, B. B. see DAVIS, D.KLEINBLOESEM, C. H., VAN BRUMMELEN, P., SAND-BERG, T. W. H. & BRIEMER, D. D. Pharmacokineticland haemodynamic interaction between nifedipineand propranolol, 537P

KLOTZ, U., DUKA, T. H., DOROW, R. & DOENICKE, A.Flunitrazepam and lorametazepam do not affect thepharmacokinetics of the benzodiazepine antagonistRo 15-1788, 95

KNOPES, K. D. see MCCLEOD, A. A.KONDOWE, G. B., KELLY, J. G. & JOHNSTON, G. D.The effect of chronic captopril therapy on plateletangiotensin II receptor density and angiotensindose-response characteristics in man, 133P

KOVACS, I. B. see SOWEMIMO-COKER, S. 0.KRAMER, H. J. see DUSING, R.KRAMER, P. A. see CHAPRON, D. J.KRIKLER, D. M. see FINDLAY, I. N.KROBOTH, P. D., SMITH, R. B., SILVER, M. R.,RAULT, R., SORKIN, M. I., PUSCHErT, J. B. & JUHL,R. P. Effects of end stage renal disease and alumi-nium hydroxide on triazolam pharmacokinetics, 839

Ku, J. see HONG, C. Y.KUMANA, C. R. & OGLE, C. W. A class experiment in

clinical pharmacology using ,B-adrenoceptor anta-gonist drugs, 169

KwON, H.-R. see CURRY, S. H.

LADER, M. H. Treatment of affective disorders, 29SLADER, M. H. see CREEK, R. A.LAIDLAW, J. see MacPHEE, G. J. A.LAND, G. see WHITEMAN, P. D.LANGENBUCHER, F. & MYSTICKA, J. In vitro and in vivo

deconvolution assessment of drug release kine-tics from oxprenolol Oros preparations, 151S

LANT, A. F. see McNABB, W. R.LARMOUR, I., JACKSON, B., CUBELA, R. & JOHNSTON,

C. I. Enalapril (MK421) activation in man: import-ance of liver status, 701

LAUGHER, S. J. see JACK, D. B.LAURENCE, D. R. & SHAW, I. C. A pharmacologist's

glossary, 587PLAWRIE, T. D. V. see RAE, A. P.LAWSON, D. H. see SMITH, A. R.LEAHEY, W. J. see COOPER, S. J.LEAHEY, W. J. see JOHNSTON, G. D.LECAILLON, J. B., MASSIAS, P., SCHOELLER, J. P. &ABADIE, F. Influence of food on the absorption of

metoprolol administered as an Oros drug deliverysystem to man, 245S

LEE, D. A. H. see EHSANULLAH, M.LEE, E. J. D., WILLIAMS, K., DAY, R., GRAHAM, G. &CHAMPION, D. Stereoselective disposition of ibu-profen enantiomers in man, 669

LEE, M. R. see HARVEY, J. N.LEE, M. R. see WORTH, D. P.LEE, P. see JACKSON, N. C.LEES, J. see CLAYTON, J. K.LEES, K. R. & REID, J. L. Single and multiple adminis-

tration of an angiotensin converting enzyme inhibi-tor, S-9490-3, in normotensive subjects, 132P

LEES, K. R. see HOCKINGS, N.LEESON, L. J. see GOOD, W.LENNARD, M. S. see BAX, N. D. S.LENNARD, M. S. see LEWIS, R. V.LENNARD, M. S. see McGOURTY, J. C.LEONARD, B. E. see O'CONNOR, W. T.LEOPOLD, D., WEBB, D., Buss, D. C., FIFIELD, R. A.,

SMITH, A. P. & ROUTLEDGE, P. A. The ex vivoplasma protein binding of theophylline in renaldisease, 823.

LEROY, D. see GODBILLON, J.LETLEY, E. see HAMILTON, M. J.LEWIS, R. V., JACKSON, P. R. & RAMSAY, L. E.Measuring side-effects of 13-adrenoceptor blockers:a comparison of two methods, 136P

LEWIS, R. V., JACKSON, P. R. & RAMSAY, L. E.Measuring side-effects of ,B-adrenoceptor receptorantagonists: a comparison of two methods, 826

LEWIS, R. V., JACKSON, P. R. & RAMSAY, L. E. Phar-macokinetics and pharmacodynamics of nifedipineand debrisoquine oxidation phenotype, 562P

LEWIS, R. V., JACKSON, P. R. & RAMSAY, L. E. Side-effects of 3-adrenoceptor blocking drugs assessedby visual analogue scales, 255

LEWIS, R. V., JACKSON, P. R. & RAMSAY, L. E. Why dosome hypertensive patients feel unwell? 562P

LEWIS, R. V., LENNARD, M. S., JACKSON, P. R.,TUCKER, G. T., RAMSAY, L. E. & WOODS, H. F.Timolol and atenolol: relationships betweenoxidation phenotype, pharmacokinetics andpharmacodynamics, 329

LEWIS, R. V. see JACKSON, P. R.LIGHT, B. see GUAY, D. R. P.LILLYWHITE, K. J. see WING, L. M. H.LINDGREN, S. see EVALDSON, G. R.LISTER, R. G. see FILE, S. E.LTTLEWOOD, J. T., GLOVER, V. & SANDLER, M. Redwine contains a potent inhibitor of phenolsulpho-transferase, 275

LoFr, S., HAXHOLDT, 0. & D0SSING, M.Antipyrine clearance in children from single salivasamples, 698

LOGAN, L. see COOK, P. J.LONGMORE, J., SZABADI, E. & BRADSHAW, C. M.Comparison of the effects of binodaline and amitrip-tyline on peripheral autonomic functions in healthyvolunteers, 295

LONGMORE, J., SZABADI, E. & BRADSHAW, C. M.Effects of binodaline on autonomic functions inhuman volunteers: comparison with amitriptylineand placebo, 592P

LOOAREESUWAN, S. see WARD, S. A.

LUDGIN, J. R. see RrrrER, J. M.LUMLEY, P. see THOMAS, M.

MacFARLANE, A. J. see BLAND, J. M.MaCFARLANE, C. M. see SHAPHERD, E. G.MacKAY, A. D. see CHAN, E.MacKINTOSH, D. & BUCHANAN, N. Excretion of diso-pyramide in human breast milk, 856L

MacLEOD, D., WATHEN, C. G., TUCKER, L., MUIR,A. L. & HILL, T. W. K. Felodipine, a potent calciumantagonist for use in hypertension, 535P

MacMAHON, B., BAKSHI, M., BRANAGAN, P., KELLY,J. G. & WALSH, M. J. Pharmakokinetics and

haemodynamic effects of tocainide in patients with

acute myocardial infarction complicated by left ven-

tricular failure, 429MACONOCHIE, J. G., FOWLER, P. A., OXFORD, J. &

FORSTER, J. K. The relationship between salbutamolplasma levels and pharmacological effect, 575P

MACONOCHIE, J. G. see THOMAS, M.

MaCPHEE, G. J. A., GOLDIE, C., RALSTON, D.,POT-TER, L., AGNEW, E., LAIDLAW, J. & BRODIE, M.

J. Effect of carbamazepine on psychomotor func-

tion in healthy subjects, 584PMaCPHEE, G. J. A. see BRODIE, M. J.MaCPHERSON, P. see BRODIE, M. J.

MaCWALTER, R. S., EL DEBANI, A. H., FEELY, J. &

STEVENSON, H. Potentiation by ranitidine of the

hypoglycaemic response to glipizide in diabetic

patients, 121PMADDERN, G. J., HOROwrrz, M. & JAMIESON, G. G.The effect of domperidone on oesophagealemptying in diabetic autonomic neuropathy, 441

MADDOCKS, J. L. & AL-SAFI, S. A. Lack of inhibition

of purine nucleoside phosphorylase and adenosine

deaminase in patients treated with azathioprine, 108

MADDOCKS, J. L. see AL-SAFI, S. A.

MAGGS, J. L. & PARK, B. K. A comparative study of

biliary and urinary metabolites of (3H]-17a-ethinyloestradiol in women, 146P

MAJID, A. see DAVISON, K.

MALAN, J., MONCRIEFF, J. & BOSCH, E. Chronophar-macokinetics of paracetamol on normal subjects,843

MALAN, L. see SHEPHERD, E. G.MALCHOW, H. see ANTONIN, K.-H.MANGIAVACCHI, M. see GHIRHARDI, P.

MARSDEN, J. T. see HOLT, D. W.MARSHALL, R. W. see ALI, N.MARSHALL, R. W. see GRImTHS, A. N.MARTIN, B. K. Effect of ranitidine on procainamide

disposition, 858LMASSIAS, P. see LECAILLON, J. B.MATLIS, R. see GREENBLATr, D. J.MATrHEY, F., PERRETF, D., GREENWOOD, R. N. &BAKER, R. I. The use of D-pencillamine in haemo-dialysis patients with rheumatoid arthritis, 557P

MATIE, H. see OVERBOSCH, D.MCBURNEY, A., FARROW, P. R., AINSWORTH, S. &WARD, W. Serum concentrations and urinary excre-

tion of pinacidil and its major metabolite, pinacidilpyridine-N-oxide following i.v. and oral administra-tion in healthy volunteers, 91

MCCLEAN, E. see FEE, J. P. H.MCCLELLAND, G. R. & RAPrOPOULOS, P. Psychomotoi

Index 871effects of paroxetine and amitriptyline, alone and incombination with ethanol, 578P

MCCLELLAND, G.R. & SuTTON, J. A. Promotion ofnormal, liquid, gastric emptying by oral metoclop-ramide detected by epigastric impedance, 151P

MCCLEOD, A. A., KNOPES, K. D., SHAND, D.G. &SANDERS-WILLIAMS, R. ,B1-selective and non-selec-tive P-adrenoceptor blockade, anaerobic thresholdand respiratory gas exchange during exercise 13

McDEvrrr, D. G. see ARNOLD, J. M. 0.McDEvrrr, D. G. see KELLY, J. G.McDEvIrT, D. G. see O'CONNOR, P. C.McEWEN, J. see NG, V. K. K.MCGILL, P. E. see DUNAGAN, F. M.McGOURTY, J. C., SILAS, J. H., LENNARD, M. S.,TUCKER, G. T. & WOODS, H. F. Metoprolol meta-bolism and debrisoquine polymorphism-a popu-lation study, 547P

McGOVERN, E. M. see BRYSON, S. M.MCINNES, G. T., BUNTING, E. A., INGS, R. M. J.,ROBINSON, J. & ANKIER, S. I. Pharmacokinetics andpharmacodynamics following single and repeatednightly administrations of loprazolam, a new benzo-diazepine hypnotic, 649

MCINNES, G. T., THOMSON, G. D., THOMPSON, G. G.,BRODIE, M. J. & MURRAY, G. D. Oral verapamilin propranolol treated subjects, 564P

MCINNES, G. T. see SMITH, A. R.MCINTOSH, M. see SMITH, A. R.McLEAN, A. E. M. see FITHARRIS, P.MCLEAN, A. J. see MORGAN, D. J.MCLEAN, S. see PETERSON, G. M.MCMURDO, M. E. T. see NG, V. K. K.MCNABB, W. R., NOORMOHAMED, F. H., BROOKS,

B. A., TILL, A. E. & LANT, A. F. Effects of repeateddoses of enalapril on renal function in man, 353

MCNEILL, A. J. see PRINGLE, T. H.MCNEILL, J. see NICHOLLS, D. P.MEATHERALL, R. C. see GUAY, D. R. P.MEEKER, J. B. see GOOD, W.MEKKI, Q. A., ABRAMS, S. M. L., PETOUNIS, A. D. &TURNER, P. Indomethacin does not attenuate theoccular hypotensive effect of timolol, 523L

MELANDER, A. see NITELIUS, E.MERDJAN, H., BAUMELOU, A., DIQUET, B., CHICK, 0.& SINGLAS, E. Pharmacokinetics of ornidazole inpatients with renal insufficiency influence of haemo-dialysis and peritoneal dialysis, 211

MEREDITH, P. A., KELMAN, A. W., ELLIOTT, H. L. &REID, J. L. Trimazosin effect modelling: an alterna-tive approach, 141P

MEREDITH, P. A., ELLIOTT, H. L., KELMAN, A. W. &REID, J. L. Doxazosin concentration-effect rela-tionships, 541P

METRA, M. see GHIRHARDI, P.MICHAEL, M. see THOMAS, M.MIHALY, G. W., WARD, S. A., EDWARDS, G.,NICHOLL, D. D., ORME, M. L'E. & BRECKENRIDGE,A. M. Pharmacokinetics of primaquine in man. I.Studies of the absolute bioavailability and effects ofdose size, 745

MIHALY, G. W. see WARD, S. A.MIHINDUKULASURIYA, J. see WALLER, D. G.MILLINGEN, K. S. see PETERSON, G. M.MINERS, J. 0. see WING, L. M. H.

872 IndexMINOLI, G. see TERRUZZI, V.MIRAKHUR, R. K. see GIBSON, F. M.MITCHELL, J. R. see SCHWARTZ, J. B.MITCHELL, P. see KAYE, C. M.MONCRIEFF, J. see MALAN, J.MONTANARI, G. see FURLANUT, M.MOPPERT, J., DEGEN, P. H. & RACINE-POON, A. Pre-

dosing plasma concentrations and 13-adrenoceptorblocking effects during repeated once daily dosingwith 160 mg sustained-release propranolol (InderalLA) and 16/260 oxprenolol Oros in healthy volun-teers, 197S

MOPPERT, J. see GODBILLON, J.MOPPERT, J. see JOHN, V. A.MOPPERT, J. see RACINE-POON, A.MORELAND, T. A. see NG, V. K. K.MORERA, J. M. see DOMENECH, J.MORGAN, D. J., RAYMOND, K. & MCLEAN, A. J. In-

fluence of chronic dosing on theophylline clearance,713L

MORrrz, J. see DUSING, R.MORRISON, L. see SHEPHERD, A. N.MORRISON, P. J. see BRADBROOK, I. D.MORRISON, R. see O'BRIEN, P. M. S.MORSE, D. S. see ABERNETHY, D. R.MORTON, P. B. see O'NEILL, P. A.MOUTON, W. see SHEPHERD, E. G.MUIR, A. L. see MacLEOD, D.MUIR, S. E. see BRODIE, M. J.MULLANE, J. see COELHO, J.MULLER, F. B., ALLSOPP, L. F., COOPER, G. L., BOLLI,

P., FREI, P., GLAUS, L., Rrrz, R. & BUHLER, F. R.Exercise and resting blood pressure and heart ratechanges 24 h after dosing in patients with essentialhypertension receiving 16/260 oxprenolol Oros oncedaily, 207S

MURRAY, G. D. see MCINNES, G. T.MURRAY, S. see SHAFFER, J. L.MURRAY, S. see BOOBIS, A. R.MYRBACK, R. E. see FARA, J. W.MYSTICKA, J. see LANGENBUCHER, F.

NESPOLI, M. see TERRUZZI, V.NEUGEBAUER, G. see STAIGER, CSC.NG, V. K. K., YAP, L. S., MORELAND, T. A.,MCMURDO, M. E. T. & McEwEN, J. Investigation ofcircadian variation in ethanol kinetics and dynamicsin healthy volunteers, 147P

NICHOLL, D. D. see MIHALY, G. W.NICHOLLS, D. P., McNEILL, J., HARRON, D. W. G. &

SHANKS, R. G. Cardiovascular effects of pinacidiland propranolol in normal man, 538P

NICHOLLS, D. P. see HARRON, D. W. G.NICHOLLS, D. P. see JOHNSTON, G. D.NICHOLSON, A. N. & STONE, B. M. Antihistamines and

drowsiness: impaired performance and the ten-dency to sleep, 127P

NICHOLSON, A. N., PASCOE, P. A. & STONE, B. M.Studies on sleep with 5-hydroxytriptaminergic andnoradrenergic uptake inhibitors, 126P

NICHOLSON, A. N. see BREIMER, D. D.NITELIUS, E., MELANDER, A., WAHLIN-BOLL, E.

Pharmacokinetic interaction of acetylsalicylic acidand dipyridamole, 379

NOORMOHAMED, F. H. see McNABB, W. R.

NORD, C.-E. see EVALDSON, G. R.NORDIN, C., SIWERS, B., BENITEZ, J. & BERTILSSON, L.Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients-rela-tionship to the debrisoquine hydroxylation meta-bolic ratio, 832

NUNN, B., BAIRD, A. & CHAMBERLAIN, P. D. Effect oftemocillin and moxalactum on platelet responsive-ness and bleeding time in normal volunteers, 568P

NuTr, D. J., FRASER, S., GOSDEN, B., STUMP, K. &ELLIOTT, J. M. Benzodiazepines and human plateletreceptor binding, 554P

NYBERG, G. Anti-anginal and anti-ischaemic effects(immediate and 1 and 3 h post-dose) of sublingual,buccal and transdermal nitroglycerine, 559P

NYEMITEI-ADDO, I., SPALDING, D. J., EWEN, S. W.,PETRIE, J. C. & HAWKSWORTH, G. M. Relaxanteffects of hydralazine and its hydrazones to potas-sium and noradrenaline in human arterial prepara-tions, 135P

OBACH, R., see DOMNECH, J.O'BOYLE, C. A., HARRIS, D., BARRY, H. & CULLEN, J.

Benzodiazepine anxiolysis in real-life stress: oraltemazepam and intravenous diazepam in oral sur-

gery, 582PO'BRIEN, P. M. S., MORRISON, R. & BROUGHTONPIPKIN, F. The effect of dietary supplementationwith linoleic and gammalinolenic acids on thepressor response to angiotensin II-a possible rolein pregnancy-induced hypertension, 335

O'CONNOR, P. C., ARNOLD, J. M. O., BROWN, A. N.,FRANCIS, R. J., FINCH, M. B., GALLOWAY, D. B.,HARRON, D. W. G., McDEvrrr, D. G. & SHANKS,R. G. Human pharmacokinetic and pharmaco-dynamic studies on Ro31-1118, a new 0-adreno-ceptor antagonist, 319

O'CONNOR, P. C. see ARNOLD, J. M. 0.O'CONNOR, P. C. see JOHNSTON, G. D.O'CONNOR, P. C. see PRINGLE, T. H.O'CONNOR, W. T., EARLEY, B. & LEONARD, B. E.

Antidepressant properties of the triazolobenzo-diazepines alprazolam and adinazolam: studies onthe olfactory bulbectomized rat model of de-pression, 45S

O'DONNELL, M. L. see WOODS, K. L.OGLE, C. W. see KUMANA, C. R.O'HARA, N. see BRINKMANN, M.OHNHAUS, E. E. see BROCKMEYER, N.OLKKOLA, K. T. Effect of charcoal-drug ratio on anti-

dotal efficacy of oral activated charcoal in man, 767O'MALLEY, K. see CROWE, M. J.O'NEILL, P. A., MORTON, P. B. & STARK, R. D. Chlor-promazine- a specific effect on breathlessness? 793

O'NEILL, P. A., STARK, R. D., RUSSELL, N. J. W.,HEAPY, C. G. & STRETTON, T. B. Efforts to elucidatethe role of type J receptors in dyspnoea, 575P

O'REILLY, R. see CHAN, E.ORME, M. L'E. see BACK, D. J.ORME, M. L'E. see EDWARDS, G.ORME, L'E. see GRIMMER, S. F.ORME, M.L'E. see MIHALY, G. W.ORME, M.L'E. see STEAD, R. J.ORME, M.L'E. see WARD, S. A.OVERBOSCH, D., MAIE, H. & VAN FURTH, R.

Comparative pharmacodynamics and clinicalpharmacokinetics of phenoxymethylpenicillinand pheneticillin, 657

OWEN, R. see HAMILTON, M. J.OXFORD, J. see MACONOCHIE, J. G.

PARINI, J. see PERUCCA, E.PARK, B. K. see MAGGS, J. L.PARR, G. see EVANS, N. J.PASANISI, F., ELLIOTT, H. L. & REID, J. L. The effects

of nicardipine hydrochloride on the pressor andaldosterone responses to angiotensin II, 139P

PASCOE, P. A. see NICHOLSON, A. N.PASIC, J., JOHNSTON, A., JACKSON, S. H. D., DOWNEY,K. M., PEVEREL-COOPER, C. .A., CHAPUT DESAINTONGE, D. M. & TURNER, P. Chronic oral theo-phylline and i.v. erythromycin interaction? 120P

PATRICK, J. M., WHARRAD, H. J., WILSON, C. G. &BIRMINGHAM, A. T. The effect of a week's ,-adrenoceptor antagonism on daytime heart-rates,subjective responses to exercise, and physicalactivity in normal subjects, 177

PATSCHEKE, H. see STAIGER, CSC.

PECK, A. W. see HAMILTON, M. J.PEGG, M. see CHAN, E.PELKONEN, O., SOTANIEMI, E. A. & AHOKASS, J. T.Coumarin 7-hydroxylase activity in human livermicrosomes. Properties of the enzyme and inter-species comparisons, 59

PERRETF, D. see MATTHEY, F.PERUCCA, E., ALBRICI, A., PARINI, J., VISCONTI, M. &FERRERO, E. Pharmacokinetics of the nootropicdrug oxiracetam in the elderly, 577P

PETERSON, G. M., MCLEAN, S., VON Wrr, R. J. &MILLINGEN, K. S. Audit of a monitoring service forfree phenytoin, 693

PETOUNIS, A. D. see MEKKI, Q. A.PETRIE, J. C. see NYEMITEI-ADDO, I.

PETRIE, J. C. see ROBB, 0. J.PEVEREL-COOPER, C. A. see PASIC, J.PHILLIPS, R. E. see WARD, S. A.PICKLES, H. G. The assessment of drug advertise-

ments: an exercise for students, 152PPIPER, P. J. see ZAKRZEWSKI, J. T.PLA DELFINA, J. M. see DOMEENECH, J.PLATT, T. B. see CREASY, W. A.

PLEUVRY, B. J. see SHAFFER, J. L.POLLARD, P. see EHSANULLAH, M.POSNER, J., ASHBY, L., COHEN, A. F. & WARWICK, S.

Methods of assessing potential risk of sedative drugsto drivers, 127P

POSNER, J. see WHITEMAN, P. D.POTTER, L. see MacPHEE, G. J. A.PRICE, D., SINGLETON, S., COOKE, J. & FEELY, M.

Hospital outpatients: who knows what drugs theyare taking, 586P

PRICHARD, B. N. C. see TOMLINSON, B.PRICHARD, B. N. C. see WALDEN, R. J.PRINGLE, T. H., O'CONNOR, P. C., MCNEIL, A. J.,RIDDEL, J. D. & SHANKS, R. G. 3-adrenoceptorblocking activity and cardioselectivity in man of ICI141,292, 137P

PUSCHETT, J. B. see KROBOTH, P. D.

Index 873RACINE-POON, A. & MOPPERT, J. Concentration-effect

relationship of oxprenolol in healthy volunteers: aretrospective analysis, 143S

RACINE-POON, A. see MOPPERT, J.RAE, A. P., BEATTIE, J. M., LAWRIE, T. D. V. &HUTTON, I. Comparative clinical efficacy of bepridil,propranolol and placebo in patients with chronicstable angina, 343

RALSTON, D. see MacPHEE, G. J. A.RAMAGE, J. K., DENTON, A. & WILLIAMS, J. G. Inhi-

bition of food stimulated acid secretion bymisoprostol, an orally active synthetic El analogueprostaglandin, 9

RAMSAY, L. E. see JACKSON, P. R.RAMSAY, L. E. see LEWIS, R. V.RAMSAY, L. E. see TONER, J. M.RANE, A. T. see EVALDSON, G. R.RANE, A. see SAWE, J.RAPTOPOULOS, P. see MCCLELLAND, G. R.RAULT, R. see KROBOTH, P. D.RAYMOND, K. see MORGAN, D. J.READ, N. W. see HOLGATE, A. M.REID, J. L. see HOCKINGS, N.REID, J. L. see JONES, C. R.REID, J. L. see LEES, K. R.REID, J. L. see MEREDITH, P. A.REID, J. L. see PASANISI, F.REID, K. E. see HOLT, D. W.RENNIE, M. J. see EDWARDS, R. H. T.REYNOLDS, G. see JACKSON, N. C.RICHARD, J. see GODBILLON, J.RICHENS, A. see ALI, N.RICHENS, A. see GRIFFITHS, A. N.RICHMOND, G. Computers working for medicine, 21SRICHWALD, G. A. see FLEISS, P. M.RIDDELL, J. G., HARRON, D. W. G. & SHANKS, R. G.Comparative effects of adimolol, labetalol andpropranolol on heart rate and blood pressure inman, 405

RIDDELL, J. G., HARRON, D. W. G. & SHANKS, R. G.Comparative effects of adimolol (MEN 935),labetalol and propranolol on heart rate and bloodpressure in man, 142P

RIDDELL, J. G. see ARNOLD, J. M. 0.RIDDELL, J. G. see PRINGLE, T. H.RrlT`ER, J. M., LUDGIN, J. R., SCHARSCHMIDT, L. A.,SMITH, R. D. & DUNN, M. J. Effects in man of athiazolidine prostaglandin analogue L-644, 122,550P

Rrrz, R. see MOLLER, F. B.ROBB, 0. J., PETRIE, J. C., WEBSTER, J. & HARRY, J. ICI

118551 does not reduce BP in hypertensive patientsresponsive to atenolol and propranolol, 541P

ROBERTS, C. J. C. see CHANNER, K. S.ROBERTS, C. J. C. see ENE, M. D.ROBERTS, M. S. see DAWSON, M.ROBERTSON, J. I. S. see CLELAND, J. G. F.ROBINSON, F. P. see DUNDEE, J. W.ROBINSON, J. see MCINNES, G. T.ROBINSON, P. see VANDENBURG, M. J.ROBINSON, P. J. see VANDENBURG, M. J.ROGERS, H. see BENNETT, P. N.ROGERS, H. J. see BRADBROOK, I. D.ROGERS, S. M. see BACK, D. J.ROGERSON, M. E. see HOLT, D. W.

874 IndexRONGIER, M. see VIDON, N.RossINI, A. see TERRUZZI, J.ROUTLEDGE, P. A. see Buss, D. C.ROUTLEDGE, P. A. see DAVIS, D.ROUTLEDGE, P. A. see EL-BAHIE, N.ROUTLEDGE, P. A. see LEOPOLD, D.ROUTLEDGE, P. A. see WATT, A. H.ROWLAND, M. see CHAN, E.RUSCA, F. see FURLANUT, M.RUSSELL, N. J. W. see O'NEILL, P. A.RurrER, N. see EVANS, N. J.RYLANCE, G. W., GARD, P. R. & EDWARDS, C.

Steady-state carbamazepine 10, 1 1-epoxide concen-trations in children, 126P

SALEM, S. A. M. see KELLY, J. G.SAMARASINGHE, H. T. see CHAN, K.SANDBERG, T. W. H. see KLEINBLOESEN, C. H.SANDERS WILLIAMS, R. see MCCLEOD, A. A.SANDLER, M. see BOYCE, M.SANDLER, M. see LITTLEWOOD, J. T.SAkWE, J., KAGER, L., SVENSSON, ENG, J.-O., & RANE,A. Oral morphine in cancer patients: in vivokinetics and in vitro hepatic glucoreduction, 495

SAWERS, S. J. A. see BLANCHARD, J.SCAVONE, J. M. see GREENBLATT, D. J.SCHACHTER, M., GEANEY, D. P., GRAHAME-SMITH,D. G., COWEN, P. J. & ELLIOTT, J. M. Increasedplatelet membrane [3H]-LSD binding in patients onchronic neuroleptic treatment, 453

SCHARSCHMIDT, L. A. see RrITER, J. M.SCHEMUTH, R. see BRINKMANN, M.SCHEURLEN, M. see ANTONIN, K.-H.SCHNELLE, K. see COELHO, J.SCHOELLER, J. P. see EVARD, D.SCHOELLER, J. P. see GODBILLON, J.SCHOELLER, J. P. see JOBIN, G.SCHOELLER, J. P. see LECAILLON, J. B.SCHOELLER, J. P. see VIDON, N.SCHOENMAKER, R. see JONKMAN, J. H. G.SCOBIE, G. see BRODIE, M. J.SCOTT, A. K., CANNON, J. & BRECKENRIDGE, A. M.Lack of effect of influenza vaccination on warfarinin healthy volunteers, 144P

SCHWARTZ, J. B., ABERNETHY, D. R., TAYLOR, A. A.& MITCHELL, J. R. An investigation of the cause ofaccumulation of verapamil during regular dosing inpatients, 512

SEALE, J. P. see HUGHES, J. M.SEDDON, T. see TEE, L. B. G.SELLERS, E. M., HAMILTON, C. A., KAPLAN, H. L.,DEGANI, N. C. & FOLTZ, R. L. Pharmacokineticinteraction of propoxyphene with ethanol, 398

SENIOR, J. see CLAYTON, J. K.SHADER, R. I. see ABERNETHY, D. R.SHADER, R. I. see GREENBLATT, D. J.SHAFFER, J. L. & HOUSTON, J. B. The effect of rifampi-

cin of sulphapyridine plasma concentrations follow-ing sulphasalazine administration, 526L

SHAFFER, J. L., PLEUVRY, B. J., DAVIES, D. S. &MURRAY, S. A comparison ofstandard and sustainedrelease clonidine with respect to plasma concen-tration and blood pressure changes, 524L

SHAND, D. G. see DAVIS, D.SHAND, D. G. see McLEOD, A. A.

SHANKS, R. G. see ARNOLD, J. M. 0.SHANKS, R. G. see HARRON, D. W. G.SHANKS, R. G. see JOHNSTON, G. D.SHANKS, R. G. see KELLY, J. G.SHANKS, R. G. see NICHOLLS, D. P.SHANKS, R. G. see O'CONNOR, P. C.SHANKS, R. G. see PRINGLE, T. H.SHANKS, R. G. see RIDDELL, J. G.SHAW, I. C. see LAURENCE, D. R.SHEARMAN, D. J. C. see HOROWITz, M.SHEPHERD, A. N., HAYES, P. C., JACYNA, M., MORRI-

SON, L. & BOUCHIER, A. D. The influence ofcaptopril, the nitrates and propranolol on apparentliver blood flow, 393

SHEPHERD, E. G., MALAN, L., MacFARLANE, C. M.,MOUTON, W. & JOUBERT, J. R. Lung function andplasma levels of thromboxane B2, 6-ketoprosta-glandin Fc,, and ,I-thromboglobulin in antigen-induced asthma before and after indomethacin pre-treatment, 459

SHORT, S. M. see WALDMANN, C. S.SHOTrON, P. A. see GRAINGER, S. L.SHOTTON, P. A. see JOHN, V. A.SHOTTON, P. A. see WARRINGTON, S. J.SILAS, J. H. see MCGOURTY, J. C.SILKE, B., VERMA, S. P., JACKSON, N. & TAYLOR, S. H.

Differences in haemodynamic effects of nicardipineand verapamil in coronary heart disease, 539P

SILKE, B. see JACKSON, N. C.SILKE, B. see TAYLOR, S. H.SILKE, B. see VERMA, S. P.SILVER, M. R. see KROBOTH, P. D.SIMS, A. C. P. Neurotic illness: conserving a

threatened concept, 9SSINGLAS, E. see MERDJAN, H.SINGLETON, S. see PRICE, D.SIWERS, B. see NORDIN, C.SIX, R. 0. see DUPONT, A. G.SJOVALL, J., WESTERLUND, D. & ALVAN, G. Renal

excretion of intravenously infused amoxycillin andampicillin, 191

SKEHAN, J. D., ARR, S. & VANDENBURG, M. J.Attenuation of hydralazine tachycardia bymethyldopa, 134P

SNAITH, R. P. & TAYLOR, C. M. Rating scales fordepression and anxiety: a current perspective, 17S

SMART, H. L. see KAMALI, F.SMITH, A. R., MCINNES, G. T., MCINTOSH, M. &LAWSON, D. H. Use of psychotropic drugs inmedical patients, 152P

SMITH, A. P. see LEOPOLD, D.SMITH, C. C. T. see TOMLINSON, B.SMITH, H. see GUAY, D. R. P.SMrrH, R. B. see KROBOTH, P. D.SMITH, R. D. see RrrrER, J. M.SMITH, S. E. see GRAINGER, S. L.SMITH, S. E. see JOHN, V. A.SMITH, S. R. see JACK, D. B.SMrTs, P., THIEN, TH. & VAN'T LAAR, A. The car-

diovascular effects of regular and decaffeinatedcoffee, 852

SORKIN, M. I. see KROBOTH, P. D.SOTANIEMI, E. A. see PELKONEN, 0.SOWEMIMO-COKER, S. O., KOVACS, I. B., KIRBY,

J. D. T. & TURNER, P. Effects of verapamil on

calcium-induced rigidity and on filterability of redblood cells from healthy volunteers and patientswith progressive systemic sclerosis, 731

SPALDING, D. J. see MYEMrrEI-ADDO, I.

SPARKS, R. G. see FITZHARRIS, P.

SPECTOR, R. G. see BRADBROOK, I. D.SPENCER, M. B. see BREIMER, D. D.STAIGER, CH., NEUGEBAUER, G., KAUFMANN, B.,

STREIN, K., ENDELE, R., STEGMEIER, K. &PATSCHEKE, H. The pharmacokinetic profile of thethromboxane (TSA2) antagonist BM 13.177 inhealthy volunteers, 572P

STANIFORTH, D. H. Correction equation for QTinterval, 862L

STANLEY, C. see Kaye, C. M.STARK, R. D. see O'NEILL, P. A.STEAD, R. J., BACK, D. J., GRIMMER, S. F. M., ALLEN,W. L., ORME, M. L'E., HODSON, M. E. & BATTEN,J. C. The bioavailability of contraceptive steroids inpatients with cystic fibrosis, 122P

STEGMEIER, K. see STAIGER, CSC.

STEPHENS, M. R. see WATT, A. H.STERN, M. see FLEISS, P. M.STEVENSON, I. H. see MaCWALTER, R. S.STODDARD, C. J. see BACK, D. J.STOECKEL, K., TRUEB, V., DUBACH, U. C., HEINTZ,

R. C., ASCALONE, V., FORGO, I. & HENNES, U. Lackof effect of tenoxicam on glibornuride kinetics andresponse, 249

STONE, B. M. see BREIMER, D. D.STONE, B. M. see NICHOLSON, A. N.STRAW, R. N. Brief review of published alprazolam

clinical studies, 57SSTREIN, K. see STAIGER, CH.STRETrON, T. B. see O'NEILL, P. A.STRICKER, B. H. CH., BARENDREGT, J. N. M. &CLAAS, F. H. J. Thrombocytopenia and leucopeniawith mianserin dependent antibodies, 102

STRUTHERS, A. D., BROWN, M. J., ADAMS, E. F. &DOLLERY, C. T. The plasma noradrenaline andgrowth hormone response to a-methyldopa andclonidine in hypertensive subjects, 311

STRUTHERS, A. D. see BROWN, M. J.STRYDOM, W. J. see VENTER, C. P.

STUMP, K. see BEST, N. R.STUMP, K. see NuTr, D. J.SUGERMAN, A. A. see CREASY, W. A.SUMNER, D. J. see KELMAN, A. W.SURI, A. C. see CROME, P.

SUrTON, J. A. see MCCLELLAND, G. R.SVENSSON, ENG, J.-O. see SAWE, J.SWANSON, D. R. see FARA, J. W.SWANSON, D. R. see THEEUWES, F.

SWEENEY, K. R. see CHAPRON, D. J.SZABADI, E. see BUCETA, J. M.SZABADI, E. see KERR, F. A.SZABADI, E. see LONGMORE, J.

TADEO, G. see TERRUZZI, V.TAYLOR, A. A. see SCHWARTZ, J. B.TAYLOR, C. M. see SNAITH, R. P.TAYLOR, S. H., VERMA, S. P. & SILKE, B. Haemo-dynamic effects of transdermal nitrate in left ventri-cular failure complicating acute myocardial in-farction, 560P

Index 875TAYLOR, S. H. see JACKSON, N. C.TAYLOR, S. H. see SILKE, B.TAYLOR, S. H. see VERMA, S. P.TEASDALE, E. see BRODIE, M. J.TEE, L. B. G., SEDDON, T., BOOBIS, A. R. & DAVIES,D. S. Drug metabolising activity of freshly isolatedhuman hepatocytes, 279

TEE, L. B. G. see BOOBIS, A. R.TEMPLE, D. M. see HUGHES, J. M.TEOH, R. see CHAN, K.TERRUZZI, V., MINOLI, G., TADEO, G., NESPOLI, M. &

ROsSINI, A. The influence of cimetidine and rani-tidine on the plasma lipid pattern, 846

THEEUWES, F., SWANSON, D. R., GUITTARD, G., AYER,A. & KHANNA, S. Osmotic delivery systems for theP-adrenoceptor antagonists metoprolol and ox-

prenolol: design and evaluation of systems for once-daily administration, 69S

THEOBALD, W. see JOHN, V. A.THEOPHILOPOULOS, N. see FLASKOS, J.THIEN, TH. see SMIrS, P.THOMAS, M., LUMLEY, P., HORNBY, E. J. A study to

investigate the effects of a novel thromboxanereceptor blocking drug AH 23848 on plateletaggregation ex vivo in man, 123P

THOMAS, M., MICHAEL, M., CHILTON, A., FOWLER, P.,MACONOCHIE, J. G. & WOODS, J. Effect of higherdoses of ranitidine on antipyrne metabolism inman, 543P

THOMPSON, E. M. see DUNDEE, J. W.THOMPSON, G. G. see MCINNES, G. T.THOMSON, G. D. see MCINNES, G. T.TILL, A. E. see McNABB, W. R.TJIA, J. see GRIMMER, S. F.TjIA, J. see WINSTANLEY, P. A.TOMLINSON, B., CRONIN, C. J., GRAHAM, B. R., SMITH,

C. C. T. & PRICHARD, B. N. C. Haemodynamics andpharmacokinetics of carvedilol (BM 14,190), 566P

TONER, J. M. & RAMSAY, L. E. Pharmacokinetics ofpotassium chloride in wax-based and syrup forms,145P

TONER, J. M. & RAMSAY, L. E. Pharmacokinetics ofpotassium chloride in wax-based and syrup formu-lations, 489

TRIGGS, E. J. see Ho, P. C.TRUEB, V. see STOECKEL, K.TUCKER, G. T. see BAX, N. D. S.TUCKER, G. T. see MCGOURTY, J. C.TUCKER, L. see MacLEOD, D.TUCKWELL, V. see HOROWITZ, M.TURNER, P. see BENNETT, P. N.TURNER, P. see DEBBAS, N. M. G.TURNER, P. see HASSAN, S. M.TURNER, P. see KILFEATHER, S. A.TURNER, P. see MEKKI, Q. A.TURNER, P. see PASIC, J.TURNER, P. see SOWEMIMO-COKER, S. 0.

VAN BRUMMELEN, P. see KLEINBLOESEM, C. H.VAN DER BOON, W. J. V. see JONKMAN, J. H. G.VANDENBURG, M. J., ROBINSON, P., ARR, S. &COOPER, W. Effects of angiotensin convertingenzyme inhibition on the increase in serum potas-sium associated with exercise, 134P

VANDENBURG, M. J., ROBINSON, P. J., COOPER, W. D.,

876 IndexARR, S. M. & CURRIE, W. J. C. The effect of angio-tensin converting enzyme inhibition on plasma metenkaphalins at rest and on exercise, 567P

VANDENBURG, M. J. see SKEHAN, J. D.VAN FURTH, R. see OVERBOSCH, D.VAN'T LARR, A. see SMITS, P.VEDIN, A. see BERGSTRAND, R.VENTER, C. P., DAYA, S., JOUBERT, P. H. & STRYDOM,W. J. Ethnic differences in human lymphocyticcyclic AMP production after isprenaline stimulationand propranolol blockade, 187

VENTURA, L. see COELHO, J.VERGHESE, C. see WALDMAN, C. S.VERMA, S. P., SILKE, B. & TAYLOR, S. H. Haemo-dynamic dose-response effects of amrinone in leftventricular failure complicating myocardial in-farction, 540P

VERMA, S. P. see JACKSON, N. C.VERMA, S. P. see SILKE, B.VERMA, S. P. see TAYLOR, S. H.VERNON-ROBERTS, J. see HOROWITZ, M.VIDON, N., EVARD, D., GODBILLON, J., RONGIER, M.,DUVAL, M., SCHOELLER, J. P. & HIRTZ, J. Investi-gation of drug absorption from the gastrointestinaltract of man. II. Metoprolol in the jejunum andileum, 107S

VIDON, N. see EVARD, D.VIDON, N. see GODBILLON, J.VINTERSTEIN, G. see AVIRAM, M.VISCONTI, M. see PERUCCA, E.VOLO, G. see BRODIE, M. J.VON WTrr, R. J. see PETERSON, G. M.VOZEH, S. & FOLLATH, F. Influence of chronic dosingon theophylline clearance, 712L

WADDELL, G. see ENE, M. D.WAGNER, W. E. see GOOD, W.WAHLIN-BOLL, E. see NITELIUS, E.WAINSCOTT, G. see HASSAN, S. M.WALDEN, R. J., BHATrACHARJEE, P., GRAHAM, B. R.& PRITCHARD, B. N. C. Lack of antihypertensiveeffect of a new putative dopamine agonist (BK 34-530): a pilot study, 558P

WALDMANN, C. S., VERGHESE, C., SHORT, S. M.,GOLDHILL, D. R. & EVANS, S. J. W. The evaluationof domperidone and metaclopramide as antiemeticsin day care abortion patients, 307

WALKER, P. see BOYCE, M.WALLER, D. G., MIHINDUKULASURIYA, J. & WARREN,D. J. A comparison of the effects of intravenouspropranolol and nadolol on the renal response tohypertonic saline infusion, 37

WALSH, M. J. see MacMAHON, B.WARD, J. W. see McBURNEY, A.WARD, S. A., MIHALY, G. W., EDWARDS, G.,LOOAREESUWAN, S., PHulPS, R. E., CHANhAVANICH,P., WARRELL, D. A., ORME, M. L'E. &BRECKENRIDGE, A. M. Pharmacokinetics of prima-quine in man. II. Comparison of acute vs chronicdosage on Thai subjects, 751

WARD, S. A. see M:ALY, G. W.WARDLE, H. M. see WARRINGTON, S. J.WARRELL, D. A. see WARD, S. A.WARREN, D. J. see WALLER, D. G.WARREN, J. B., Cuss, F. & BARNES, P. J. Posture and

theophylline kinetics, 707

WARRINGTON, S. J., BARCLAY, S. P., JOHN, V. A.,SHOTTON, P. A., WARDLE, H. M. & GOOD, W. Influ-ence of site of drug delivery on the systemic avail-ability of metoprolol: comparison of intragastricinfusion and 14/190 Oros administration, 219S

WARRINGTON, S. J., BARCLAY, S. P., JOHN, V. A.,SHOTrON, P. A. & GOOD, W. Comparison of single-dose pharmacokinetic and pharmacodynamicproperties of two metoprolol Oros systems withdifferent initial zero-order release rates, 225S

WARRINGTON, S. J. see BENNETr, P. N.WARRINGTON, S. J. see WOODS, K. L.WARWICK, S. see POSNER, J.WATHEN, C. G. see MacLEOD, D.WATSON, T. R. see DAWSON, M.WATr, A. H., Buss, D. C., STEPHENS, M. R. &ROUTLEDGE, P. A. Amiodarone reduces plasmawarfarin clearance in man, 591P

WEATHERLEY, B. C. see FITZHARRIS, P.WEBB, D. see LEOPOLD, D.WEBSTER, J. see ROBB, 0. J.WEG, M. see BOYCE, M.WEI, Y. H. see HONG, C. Y.WEISS, M. Drug metabolite kinetics: noncompart-

mental analysis, 855LWESTERLUND, D. see SJOVALL, J.WHARRAD, H. J. see PATRICK, J. M.WHITE, K. see BRYSON, S. M.WHITE, K. F. see JONES, C. R.WHITE, R. D. see FITZHARRIS, P.WHITEMAN, P.D., BYE, A., FOWLE, A. S. E., JEAL, S.,LAND, G. & POSNER, J. Tolerance and pharmaco-kinetics of AS15U an acyclovir analogue in healthyvolunteers, 149P

WHMNG, B. see BRYSON, S. M.WHMNG, B. see DUNAGAN, F. M.WHMNG, B. see HOWIE, C. A.WHmNG, B. see KELMAN, A. W..WILHELMSSON, C. see BERGSTRAND, R.WILKINS, M. R., WYNNE, R. D. & KENDALL, M. J.A placebo controlled comparison of the effects ofpirenzipine and amitriptyline on the tyraminepressor test in health volunteers, 829

WILLIAMS, J. see EL-BAHIE, N.WILLIAMS, J. G. see RAMAGE, J. K.WILLIAMS, K. see LEE, E. J. D.WILLIAMS, P. 0. Wellcome Trust support for clinicalpharmacology in the UK, 116L

WILLIAMS, T. see ENSANULLAH, M.WILLIAMSON, P. J. see ENE, M. D.WILSON, C. G. see PATRICK, J. M.WILSON, C. M. see DUNDEE, J. W.WING, L. M. H., MINERS, J. 0. & LILLYWHITE, K. J.Verapamil disposition-effects of sulphinpyrazoneand cimetidine, 385

WINSTANLEY, P. A., ALLEN, W. L., TJIA, J., HOBSON,D., BRECKENRIDGE, A. M. & BACK, D. J. Lack ofeffect of highly purified subunit influenza vaccine ontheophylline metabolism, 569P

WOODS, H. F. see BAX, N. D. S.WOODS, H. F. see LEWIS, R. V.WOODS, H. F. see McGOURTY, J. C.WOODS J. see THoMAS, M.WOODS, K. L., JACK, D. B., KENDALL, M. J., HALSEY,

A., O'DONNELL, M. L., WARRINGTON, S. J. & JOHN,V. A. A multiple dose comparative study of the

Index 877pharmacodynamic and pharmacokinetic behaviour YAP, L. S. see NG, V. K. K.of polymer-matrix and Oros dosage forms ofoxprenolol in healthy volunteers, 177S ZAK, S. L. see GOOD, W.

WOOrTON, R. see FTHARRIS, P. ZAKRZEWSKI, J. T., BARNES, N. C., PIPER, P. J. &WORTH, D. P., AL-SHARMA, Y., HARVEY, J. N., COSTELLO, J. F. Quantitation of leukotrienes inHAINSWORTH, R. & LEE, M. R. Renal haemo- asthmatic sputum, 549Pdynamics and cardiac output in essential hyper- ZAKRZEWSKI, J. T., BARNES, N. C., PIPER, P. J. &tension: the effect of oral nadolol, 130P COSTELLO, J. F. Measurement of leukotrienes in

WORTH, D. P. see HARVEY, J. N. arterial and venous blood from normal and asth-WRIGHT, J. see ALDHOUS, M. matic subjects by radioimmunoassay, 574PWu, P. see HONG, C. Y.WYmNE, R. D. see WILKINS, M. R.

SUBJECT INDEX

(S = supplement; L = letter to the Editors; P = proceedings)

A51SU, 149PAcetazolamide, 363Acetylsalicylic acid

age and sex, 675dipyridamole, 379

Activated charcoalmefenamic acid, 836

Adenosine deaminase, 108Adenosineasthma 685

Adimolol, 142Pcardiovascular effects, 405

Adinazolam, 45Sac-adrenoceptor antagonists, 266a2-adrenoceptor, 534P, 555PP-adrenoceptor

density, 128Pmelatonin, 799

12-adrenoceptor, 534Pdesensitization, 587P

P-adrenoceptor agonists, 177, 534P, 619asthma, 787Ro31-118, 319side effects, 136P, 826

1-adrenoceptor blockers, 169, 255, 258, 411, 775,63S-212Sanxiety, 783depression, 557PISA, 588P

Affective disorders, 1S-62Salprazolam, 29S

Age, 140P, 261acetylsalicylic acid, 675oxaprozin, 373

Agonist activitypartial, 775

AH 23848, 123PAldosterone, 139PAldrin, 279Alprazolam, 21S, 37S, 45S, 51S, 57S

affective disorders, 29SAluminium hydroxide, 839Aminophylline, 528Amiodarone

warfarin clearance, 591PAmitriptyline, 295, 578P

binodaline, 592Ptyramine pressor test, 705, 829

Amoxicillin, 99, 191Ampicillin, 191Amrinone, 540PAnaerobic threshold, 13Angina pectoris, 150P

bepridil, 343Angiotensin II, 29, 139P, 335

Angiotensin converting enzyme inhibition, 134P, 353,567P, 605

AntiarrhythmicsClass III, 266

Antidepressants, 45SAntidotal efficacy

charcoal-drug ratio, 767Antiemetics, 307Antiepileptic drugs, 125PAntihistamine, 127P

drowsiness, 585PAntipyrine, 120P

clearance, 593, 698metabolism, 570P

Anti-sickling compound, 471Anxiety, 17S, 37S, 57S

carbachol, 817performance, 445, 783

ArthritisD-penicillamine, 557PNSAID concentration-effect, 548P

Ascorbic acid, 528Aspirin

midazolam, 581Pplatelet aggregation, 715

Asthma, 63102-adrenoceptor agonist, 787antigen-induced, 459

Asthmatics, 549Pleukotriene concentrations, 574P

Atenolol, 13, 138PICI 118551, 541Ptimolol, 429verapamil, 565P

Azathioprine, 105, 108Aztreonam, 233

pharmacokinetics, 509

Bayesian method, 546PBenzodiazepines, 95

central effects, 807depression, 31Spharmacokinetics, 649real life stress, 582Preceptor binding, 554Ptriazolam, 554P

Bepridil, 343Betaxolol, 138PBinodaline, 295, 592PBioavailability, 79, 87

oral contraceptives, 122Pprimaquine, 745

BK 34-530, 558PBlood pressure, 21, 114L

ambulatory, 129P

878

Index 879caffeine, 852

Blood-oxygen saturation curve, 471BM 13.177, 572PBM 14,190 (carvedilol), 566PBopindolol, 775Breast milk

aztreonam, 509disopyramide, 856tinidazole, 503

Breathlessnesschlorpromazine, 793

Bronchial carcinomametoclopramide, 757

Bronchoconstrictionadenosine, 685

Bucindolol, 132PBufuralol, 537PBufuralol 1'-hydroxylase

liver phenotyping, 721BW 12C, 471BW 825C, 585P

CSF concentrations, 161Caffeine, 225

decaffeinated coffee, 852sperm motility, 739

Calciumsperm motility, 739

Calcium antagonist, 45, 535PCalcium chelator, 45Calcium entry blockers, 631Calcium ionophore, 45Calmodulinsperm motility, 739

Cancermorphine, 495

Captopril, 29, 133P, 393Carbachol, 295

anxiety, 817Carbamazepine, 584PCardiac effects, 73Cardiac function, 129PCardiac output, 130PCarvedilol, 566PCatecholamines, 311blood pressure, 852

Cetamolol,-adrenoceptor blockade, 411

Charcoal-drug ratioantidotal efficacy, 767

Chlorpromazinebreathlessness, 793

CholesterolHDL, 846

Chronic dosing with theophylline, 712L, 713LChronic obstructive airways disease, 150PChronopharmacology

paracetamol, 843Ciclazindol

pupillary response, 639Cimetidine, 272plasma lipid pattern, 846verapamil disposition, 385

Circadian rhythmstheophylline, 707

Circadian variation, 147PClass III antiarrhythmic, 266Class experiment, 169Clearance methods, 29Clinical trials, 155Clonidine, 311

blood pressure, 524Coffee

cardiovascular effects, 852Collagenase dispersion, 279Congestive heart failure

ibopamine, 613Contraceptive steroids, 122PConverting enzyme, 29Coronary heart disease, 539PCoumarin 7-hydroxylase, 59Crystalluria, 191Cyclic AMP, 739

lymphocytic, 187Cyclosporin, 548PCystic fibrosis, 122PCytotoxicity assay, 102

Dazoxiben, 1Debrisoquine

depression, 8324-hydroxylase, 721hydroxylation, 832oxidation phenotype, 562Ppolymorphism, 547P

Deesterification, 701Delusions, 551PDepression, 17S, 31S, 557P, 57S

alprazolam, 31Sdebrisoquine, 832

Desipraminepupillary response, 639

Desmethylimipramine, 579Pmelatonin, 799

Dextropropoxyphene, 551PDiabetics, 121Pdomperidone, 441

Dialysismexiletine clearance, 857L

Diazepam, 51, 261, 37Smetabolism, 544Poral surgery, 582Pplasma concentrations, 581Pprotein binding, 587P

Diethylcarbamazine, 545PDigoxin vascular response, 417Diltiazam, 131PDipyridamole, 379

platelet aggregation, 715Disopyramide in breast milk, 856LDiuretics, 258Domperidone, 307

oesophageal emptying, 441Dopamine, 21, 5IPDopamine agonist, 558PDose-response, 605Doxazosin, 541PDrivers, 127PDrowsiness, 127PDrug absorption

880 Indexcolon, 113Sduodenum, 97Sfood, 119Sgastric function, 127Sileum, 107Sjejunum, 97S, 107Smetoprolol, 63S-212Soxprenolol, 63S-212Sstomach, 97S

Drug disposition, 385Drug interaction, 379, 385Drug metabolism, 279Drug release kinetics

Oros, 63S-212SDyspnoea, 575P

ECG time intervals, 860L, 861LECT, 551PEchocardiography, 435Elderly volunteers, 225, 233

acetazolamide, 363oxaprozin, 373

Enalapril, 140Pcongestive heart failure, 542Phypertension, 605liver status, 701met enkephalins, 567Prenal function, 353

Enalaprilat, 140PEnalaprilic acid (KM422), 701Enzyme inducing agents, 544PEnzyme inhibition, 589P

antipyrine clearance, 593lignocaine clearance, 597

Epigastric impedance, 151PEpinine, 143PErythromycin, 120PEthanol, 147P, 275, 551Ppropoxyphene, 398psychomotor effects, 578P

Ethinyloestradiol, 146Pbioavailability, 572P

Ethnic difference, 187mephenytoin, 483primaquine, 751

7-ethoxycoumarin, 279Ethylenediamine, 148PExaminations

anxiety, 783Exercise, 134P

chlorpromazine, 793Experimental infection, 657

Fatty acids, 335Felodipine, 535P(±)-fenfluramine, 849Fenoldopam, 21, 143PFlow rate, 67Fooddrug absorption, 119Soxprenolol, 191S

Formulation, 87Frusemide, 417

Gastric acid secretion, 9Gastric emptying 67

(±)-fenfluramine, 849Gastric function, 127SGastrointestinal absorption, 77SGenetic polymorphism, 483Glibornuride, 249Glipizide, 121PGlucoronidationmorphine, 495

Glucose, 249Growth hormone, 311Guanfacine, 534P

HI-receptor antagonist, 272Haemodialysis, 557P

omidazole, 211Haemodynamic effects, 539P

amrinone, 540Pcarvedilolmetoprolol, 239Snicardipine infusion, 563Ptocainide, 429transdermal nitrate, 560P

Heart rate, 1775-HT platelet uptake, 556PHuman hepatocytes, 279Human liver microsomes, 59Human mixed lymphocyte reaction, 105Hydralazine, 135P5-hydroxytryptamine

receptors, 453uptake, 126P

Hyoscine, 836Hypercholesterolaemia, 715Hypertension, 311, 535P, 562P

nadolol, 129Poxprenolol, 207S

Hypnotics, 649Hypoglycaemia, 121P

ICI 118, 551, 541Ptachycardia, 619

ICI 141, 292, 137PIbopamine, 143P

congestive heart failure, 613Ibuprofen stereoselection, 669Ileostomy

bioavailability, 572PImipramine binding sites, 555PIndirect immunofluorescence, 102Indocyanine green, 393Indomethacin, 459

ocular hypotensive effect, 523Indoramin, 266Influenza vaccination, 144P, 569PInsulin response, 249Interaction, 51, 99, 219Intestinal absorption, 67Intrinsic sympathomimetic activity, 588PIrritable bowel, 301Isoprenaline, 114L, 187LIsosorbide mononitrate, 393

J receptors, 575P

6-keto-prostaglandin Fl,, 459Ketotifen, 587PKineticsnoncompartmental analysis, 855Lverapamil, 512

L-644, 122, 550PLabetalol, 142P

heart rate, 405Leishmaniasis, 73Leucopenia, 102Leukotrienes

blood concentrations, 574Phuman uterus, 573Psputum, 549P

Levonorgestrel bioavailability, 572PLignocaine, 261, 589P

clearance, 597Liver blood flow, 393Liver

deesterification, 701phenotype, 721

Loprazolam 51anxiety performance, 445pharmacokinetics, 649

Lymphocyte, 534Pl32-adrenoceptor density, 587P, 588P

MEN 935, see AdimololMast cells, 631Mebendazole, 79, 87Mediator release, 711Mefenamic acid, 836Melatonin, 258

desmethylimipramine, 799oral administration, 517

Mephenytoin, 483Meptazinol, 551P6-mercaptopurine, 105Met enkephalins

enalapril, 567PMetabolism

age and sex, 675Metabolite, 91, 225Methotrexate, 569PMethoxamine pupillary response, 639Methyldopa, 134P, 311Metoclopramide, 67, 151P, 307

pharmacokinetics, 757Metoprolol, 219

absorption, 63S-212Sgastrointestinal absorption, 77Smetabolism, 547POros systems, 63S-212S

Metronidazole, 203Mexiletine clearance, 857LMianserin, 102Midazolam

ranitidine, 553Pserum binding, 581P

Misoprostol, 9Monitoring service, 693Morphine pharmacokinetics, 495Moxalactam, 568PMuscle protein synthesis, 124P

Index 881Muscular dystrophy, 124PMyelography, 161Myocardial infarction

tocainide, 429Myocardial oxygen consumption, 435

NSAID concentration-effect, 548PNadolol

hypertension, 129Poral, 130P

Nalbuphine, 580PNatriuresis, 423Neuroleptics

platelets, 453Neurotic depression, 556PNeurotic illness, 9SNicardipine, 536P, 539P

angiotensin II, 139Phaemodynamic effects, 563Phistamine release, 631pituitary hormone release, 139P

Nicotine, 239Nifedipine, 537P

debrisoquine oxidation phenotype, 562Phistamine release, 631natriuresis, 423pharmacokinetics, 562P

Nitrendipine, natriuresis, 423Nitroglycerin, 559P

posture, 403Ltransdermal, 435, 561P

Non-diuretic effects, 417Non-steroidal anti-inflammatory drugs, 155Non-compartmental analysis, 855LNoradrenaline, 534PNortriptyline

depression, 832

Obesity, 849Obsessional neurosis, 556POesophageal emptying, 441One-sample method, 698Oral contraceptive steroids, 572POrnidazole, 211Oros drug delivery systems 63S-212SOsmotic delivery systems, 63S-212SOut-patients, 37Sdrug therapy, 586P

Oxaprozin, 373Oxidation phenotype, 329Oxidation polymorphism, 721Oxiracetam, 577POxprenolol, 132POros systems, 63S-212Sconcentration-effect, 143Sdrug absorption, 137Sosmotic delivery systems, 63S-212S

Paracetamol, 113L, 590Ppharmacokinetics, 843probenecid, 590P

Paroxetine, 578Ptyramine pressor response, 705

Penbutolol, 120Pantipyrine clearance, 593

882 IndexD-Penicillamine, 557PPerceived exertion, 177Performance

anxiety, 445triazolam, 807

Peritoneal dialysis, 211PharmacodynamicsACE inhibitors, 140Patenolol, 329loprazolam, 649metoprolol 63S-212Stimolol, 329Ro31-118, 319oxprenolol 63S-212S

Pharmacokinetic interaction, 379Pharmacokinetics, 79, 91, 99

aztreonam, 233, 509diethylcarbamazine, 545Ploprazolam, 649metoclopramide, 757metoprolol 63S-212Smetronidazole, 203morphine, 495nicotine, 239ornidazole, 211oxaprozin, 373oxiracetam, 577Poxprenolol 63S-212Sparacetamol, 843parameter optimisation, 546Ppheneticillin, 657phenoxymethylpenicillin, 657potassium chloride, 145P, 489primaquine, 745, 751propoxyphene and ethanol, 398Ro31-118, 319tenoxicam, 249timolol and atenolol, 329tinidazole, 503tocainide, 429triazolam, 807, 839warfarin, 545P

Pheneticillin pharmacokinetics, 657Phenolsulphotransferase, 275Phenotype

liver, 721Phenoxymethylpenicillin

pharmacokinetics, 657Phenylephrine, 295, 405Phenytoin, 161

monitoring service, 693Physical activity, 177Pilocarpine

pupillary response, 639Pinacidil pyridine-N-oxide, 91Pinacidil, 91, 538PPindolol, 169, 537PPineal gland, 579P

melatonin, 799Pipothiazine, 576PPirenzepine

tyramine pressor test, 829Pituitary hormone release, 139PPlasma concentrations, 125PPlasma protein binding, 261

Platelet aggregation, 123Phypercholesterolaemia, 715

Platelet inhibition, 71%Platelet receptor binding, 554PPlatelets, 459human, 453temocillin and moxalactam, 568P

Post market surveillance, 21SPosture

theophylline, 707Potassium chloride, 145P

pharmacokinetics, 489Potassiumserum levels, 134P

Prednisone, 587PPregnancy toxaemia, 335Primaquine pharmacokinetics, 745, 751Probenecid, 590PProcainamide disposition, 858LProcaterol, 787Proceedings

University of Dundee, 119PUniversity of London, 533P

Promethazine, 793Propoxyphene, 51

ethanol, 398Propranolol, 13, 37, 120P, 138P, 169, 187, 537P, 538P

antipyrine clearance, 593anxiety performance, 445anxiety, 783bepridil, 343cardiovascular effects, 538Peffect comparison, 142Pheart rate, 405ICI 118551, 541Plignocaine clearance, 589P, 597vascular response, 417verapamil, 564P

Prostaglandin, 335El analogue, 9thiazolidine analogue, 550P

Protein binding, 161, 261theophylline, 529, 823

Psoriasis, 569PPsychomotor effects

zopiclone, 584PPsychomotor performance

carbamazepine, 584Ptemazepam, 583P

Psychotropic drugs, 152PPupil diameter, 295Pupillary response, 639Purine nucleoside phosphorylase, 108

OT time interval, 862L

Radioimmunoassayenalapril, 701

Ranitidine, 121P, 219, 553antipyrine metabolism, 543Pmediator release, 711Lplasma lipid pattern, 846procainamide disposition, 858L

Rating scales, 17SReceptor binding, 554P

Red cell deformability, 731Registration procedures, 155Renal disease

theophylline binding, 823triazolam, 839

Renal excretion, 191Renal failure, 203Renal function, 29, 37

enalapril, 353Renal haemodynamics

hypertension, 129, 130PRenal transplantation, 548PRenin, 335Reproducibility, 185SRespiratory gas exchange, 13Rifampicin, 526Ro 15-1788, 95Ro 31-1118, 319

S-9490-3, 132PSalbutamol, 787Salivation, 295Sclerosis, 731Secoverine, 301Sedative drugs

driving, 127PSeizure prophylaxis, 161Serum bindingmidazolam, 581P

Serum aztreonam, 509Sex, 675Short-term growth curve, 657Side effects, 177, 255

3-adrenoceptor agonists, 826nalbuphine, 580P

Sigmoid motility, 301SKF 82526, see FenoldopamSKF 82526-J, see FenoldopamSleep, 807Smoking, 239Sodium stibogluconate, 73Sperm motility, 45, 739Stanozolol, 124PStatistical methods, 155Steady-state accumulation, 512Stereoselective disposition, 669Sucralfate, 113LSulphasalazine, 526Sulphinpyrazone, 385Sweat glands, 295

carbachol, 817Symposia

Affective disorders, 1S-62SOros drug delivery systems, 63S-212S

Systolic time intervals, 536P

Tachycardia, 134PTemazepam

elderly women, 583Phalf-life, 587Poral surgery, 582Pranitidine, 553P

Temocillin, 568PTenoxicam, 249Theophylline, 99, 120P

Index 883administration, 125Pasthma, 685clearance, 712L, 713Linfluenza vaccine, 569Pposture, 707protein binding, 529

Thrombocytopenia, 1023-thromboglobulin, 45902-thromboxane, 459Thromboxane antagonist, 572PThromboxane synthetase inhibition, 1Time intervalECG correction, 860L, 861LQT correction, 862L

Timolol, 329hypotensive effect, 523

Tinidazolepharmacokinetics, 503

Tocainidehaemodynamic effects, 429

Tolerance, 272triazolam, 807

Transdermal nitrate, 560PTransdermal nitroglycerine, 435Transit time, 67

metoprolol, 77STrial size, 155Triazolam, 554P

pharmacokinetics, 839tolerance, 272

Trimazosin, 141PTriprolidine, 585PTyramine pressor response, 705, 829Tyramine pupillary response, 639

Urinary solubility, 191

Valium mixed micelles, 581PVascular effects, 131PVasoconstriction, 1Vecuronium, 552PVerapamil, 539

atenolol, 565Pdisposition, 385kinetics, 512propranolol, 564Psclerosis, 731

Viewdata, 21SVisual analogue scales, 255, 557P, 793

hypertension, 562Pside effects, 826

Warfarin, 144Pamiodarone, 591Pstereochemical aspects, 545P, 571

Wellcome Trust, support, 116L

Young volunteers, 225

Zero-order release rate, 225SZopiclone, 553Ppsychomotor effects, 584P

The British Journal of

Clinical Pharmacology

Volume 191985

Published forThe British Pharmacological Society byBlackwell Scientific Publications

( 1985 Blackwell Scientific PublicationsOsney Mead, Oxford OX2 OEL8 John Street, London WC1N 2ES23 Ainslie Place, Edinburgh EH3 6AJ52 Beacon Street, Boston, Mass. 02108, USA667 Lytton Avenue, Palo Alto, Calif. 94301, USA107 Barry Street, Carlton, Victoria 3053, Australia

Published on behalf ofThe British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or

transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise,without the prior permission of the copyright owner. Authorization to photocopy items for internal or

personal use, or the internal or personal use of specific clients, is granted by Blackwell ScientificPublications for libraries and other users registered with the Copyright Clearance Center (CCC)Transactional Reporting Service, provided that the base fee of $02.00 per copy is paid directly to CCC, 27Congress Street, Salem, MA 01970, USA. 0306-5251/85 $02.00/0. (For copying beyond that permitted bySections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying,such as copying for general distribution, for advertising or promotional purposes, for creating new

collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by Oxprint Ltd, OxfordPrinted in Great Britainat the University Press, Cambridge

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statementappears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are theresponsibility of the contributor or advertiser concerned. Accordingly, the publishers and the editorial committee and their respectiveemployees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion orstatement.